



APPROVED BY THE AUA
BOARD OF DIRECTORS JUNE
2024

Authors' disclosure of potential
conflicts of interest and
author/staff contributions appear
at the end of the article.

© 2024 by the American
Urological Association

INCONTINENCE AFTER PROSTATE TREATMENT: AUA/GURS/SUFU GUIDELINE (2019; Amended 2024)

Guideline Panel

Jaspreet S. Sandhu, MD; Benjamin N. Breyer, MD; Craig Comiter, MD; James A. Eastham, MD; Christopher Gomez, MD; Daniel J. Kirages, PT; Chris Kittle; Alvaro Lucioni, MD; Victor W. Nitti, MD; John T. Stoffel, MD; O. Lenaine Westney, MD; Kurt McCammon, MD

Amendment Panel

Benjamin N. Breyer, MD; Alex J. Vanni, MD; O. Lenaine Westney, MD

Staff and Consultants

Sennett K. Kim; Erin Kirkby, MS; Alexis Marianes, PhD; M. Hassan Murad, MD

SUMMARY

Purpose

This Guideline on incontinence after prostate treatment (IPT) is intended to facilitate care decisions and aid clinicians in the management of patients who have incontinence after undergoing treatment of localized prostate cancer and benign prostatic hyperplasia (BPH). The multiple treatments that exist for patients with IPT are discussed and evaluated herein.

Methodology

The systematic review utilized to inform this Guideline was conducted by a methodology team at the Mayo Clinic Evidence-Based Practice Research Program. The scope of the topic and the discussion of the final systematic review used to develop Guideline statements was conducted in conjunction with the Incontinence after Prostate Treatment Panel. A research librarian conducted searches in Ovid MEDLINE (from 2000 to December 21st, 2017), Cochrane Central Register of Controlled Trials (from 2000 to December 21st, 2017) and Cochrane Databases of Systematic Reviews (from 2000 to December 21st, 2017). Searches of electronic databases were supplemented by reviewing reference lists of relevant articles. Panel members identified additional references through 12/31/2018. In 2023, the Incontinence after Prostate Treatment Guideline was updated through the AUA amendment process in which newly published literature is reviewed and integrated into previously published Guidelines. The methodologist searched Embase (1996 to June 2023), EBM Reviews – Cochrane Central Register of Controlled Trials (May 2023), EBM Reviews – Cochrane database of Systematic Reviews (2005 to June 2023), Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily (2019 to June 2023).

GUIDELINE STATEMENTS

PRE-TREATMENT

1. Clinicians should inform patients undergoing localized prostate cancer treatment of all known factors that could affect continence. (*Moderate Recommendation; Evidence Level: Grade B*)
2. Clinicians should counsel patients regarding the risk of sexual arousal incontinence and climacturia following localized prostate cancer treatment. (*Strong Recommendation; Evidence Level: Grade B*)
3. Clinicians should inform patients undergoing radical prostatectomy that incontinence is expected in the short-term and generally improves to near baseline by 12 months after surgery but may persist and require treatment. (*Strong Recommendation; Evidence Level: Grade A*)
4. Prior to radical prostatectomy, clinicians may offer patients pelvic floor muscle exercises or pelvic floor muscle training. (*Conditional Recommendation; Evidence Level: Grade C*)
5. Clinicians should inform patients undergoing radical prostatectomy or transurethral resection of the prostate after radiation therapy of the high rate of urinary incontinence following these procedures. (*Moderate Recommendation; Evidence Level: Grade C*)

POST-PROSTATE TREATMENT

6. In patients who have undergone radical prostatectomy, clinicians should offer pelvic floor muscle exercises or pelvic floor muscle training in the immediate post-operative period. (*Moderate Recommendation; Evidence Level: Grade B*)
7. In patients with bothersome stress urinary incontinence after prostate treatment, clinicians may offer surgery as early as six months if incontinence is not improving despite conservative therapy. (*Conditional Recommendation; Evidence Level: Grade C*)
8. In patients with bothersome stress urinary incontinence after prostate treatment despite conservative therapy, clinicians should offer surgical treatment at one year post-prostate treatment. (*Strong Recommendation; Evidence Level: Grade B*)

EVALUATION OF INCONTINENCE AFTER PROSTATE TREATMENT

9. Clinicians should evaluate patients with incontinence after prostate treatment with history, physical exam, and appropriate diagnostic modalities to categorize type and severity of incontinence and degree of bother. (*Clinical Principle*)
10. In patients with urgency urinary incontinence or urgency predominant mixed urinary incontinence, clinicians should offer treatment options per the American Urological Association Overactive Bladder Guideline. (*Clinical Principle*)
11. Prior to surgical intervention for stress urinary incontinence, clinicians should confirm stress urinary incontinence by history, physical exam, or ancillary testing. (*Clinical Principle*)
12. Clinicians should inform patients with incontinence after prostate treatment of management options for their incontinence, including surgical and non-surgical options. (*Clinical Principle*)
13. In patients with incontinence after prostate treatment, clinicians should discuss risk, benefits, and expectations of different treatments using the shared decision-making model. (*Clinical Principle*)
14. Prior to surgical intervention for stress urinary incontinence, clinicians should perform cystourethroscopy to assess for urethral and bladder pathology that may affect outcomes of surgery. (*Expert Opinion*)

15. Clinicians may perform urodynamic testing in patients prior to surgical intervention for stress urinary incontinence in cases where it may facilitate diagnosis or counseling. (*Conditional Recommendation; Evidence Level: Grade C*)

TREATMENT OPTIONS

16. In patients seeking treatment for incontinence after radical prostatectomy, clinicians should offer pelvic floor muscle exercises or pelvic floor muscle training. (*Moderate Recommendation; Evidence Level: Grade B*)
17. Clinicians should discuss the option of artificial urinary sphincter with patients who are experiencing mild to severe stress urinary incontinence after prostate treatment. (*Strong Recommendation; Evidence Level: Grade B*)
18. Prior to implantation of artificial urinary sphincter, clinicians should ensure that patients have adequate physical and cognitive abilities to operate the device. (*Clinical Principle*)
19. In patients who select artificial urinary sphincter, clinicians should preferentially utilize a single cuff perineal approach. (*Moderate Recommendation; Evidence Level: Grade C*)
20. Clinicians should discuss the option of male slings with patients as treatment options for mild to moderate stress urinary incontinence after prostate treatment. (*Moderate Recommendation; Evidence Level: Grade B*)
21. Clinicians should not routinely implant male slings in patients with severe stress incontinence. (*Moderate Recommendation; Evidence Level: Grade C*)
22. Clinicians may offer adjustable balloon devices to non-radiated patients with mild to severe stress urinary incontinence after prostate treatment. (*Conditional Recommendation; Evidence Level: Grade C*)
23. Clinicians should manage patients with stress urinary incontinence after treatment of benign prostatic hyperplasia the same as patients that have undergone radical prostatectomy. (*Moderate Recommendation; Evidence Level: Grade C*)
24. In patients with stress urinary incontinence after primary, adjuvant, or salvage radiotherapy who are seeking surgical management, clinicians should offer artificial urinary sphincter over male slings or adjustable balloons. (*Moderate Recommendation; Evidence Level: Grade C*)
25. In patients with incontinence after prostate treatment, clinicians should counsel patients that efficacy is low and cure is rare with urethral bulking agents. (*Strong Recommendation; Evidence Level: Grade B*)
26. Clinicians should consider other potential treatments for incontinence after prostate treatment as investigational, and patients should be counseled accordingly. (*Expert Opinion*)

COMPLICATIONS AFTER SURGERY

27. Clinicians may counsel patients regarding risk factors for artificial urinary sphincter erosion. (*Conditional Recommendation; Evidence Level: Grade C*)
28. Clinicians should counsel patients that artificial urinary sphincter will likely lose effectiveness over time, and reoperations are common. (*Strong Recommendation; Evidence Level: Grade B*)
29. In patients with persistent or recurrent urinary incontinence after artificial urinary sphincter or sling, clinicians should again perform history, physical examination, and/or other investigations to determine the cause of incontinence. (*Clinical Principle*)
30. In patients with persistent or recurrent stress urinary incontinence after sling, clinicians should recommend an artificial urinary sphincter. (*Moderate Recommendation; Evidence Level: Grade C*)
31. In patients with persistent or recurrent stress urinary incontinence after artificial urinary sphincter, clinicians should discuss artificial urinary sphincter revision with the patient. (*Strong Recommendation; Evidence Level: Grade B*)

32. In patients presenting with infection or erosion of an artificial urinary sphincter or sling, clinicians should perform explantation and reimplantation should be delayed. (*Clinical Principle*)
33. After explanting an eroded device, clinicians may manage artificial urinary sphincter urethral cuff erosion intra-operatively with urethral catheter alone, in situ urethroplasty, or anastomotic urethroplasty. (*Expert Opinion*)

SPECIAL SITUATIONS

34. Clinicians should discuss urinary diversion with patients who are unable to obtain long-term quality of life due to incontinence after prostate treatment. (*Expert Opinion*)
35. In patients with bothersome incontinence during sexual activity, clinicians should offer treatment. (*Moderate Recommendation; Evidence Level: Grade C*)
36. In patients with stress urinary incontinence following urethral reconstructive surgery, clinicians may offer artificial urinary sphincter and counsel that complication rates are higher. (*Conditional Recommendation; Evidence Level: Grade C*)
37. In patients with incontinence after prostate treatment and erectile dysfunction, clinicians may offer a concomitant or staged procedure. (*Conditional Recommendation; Evidence Level: Grade C*)
38. In patients with symptomatic vesicourethral anastomotic stenosis or bladder neck contracture, clinicians should treat the patient prior to surgery for incontinence after prostate treatment. (*Clinical Principle*)

INTRODUCTION

BACKGROUND

IPT causes emotional and financial distress to patients afflicted with this condition by delaying patients' re-entry into society, inhibiting relationships, and carrying an economic burden for families and stakeholders. It is a condition that has gained visibility not only due to the extensive use of surgery for prostate cancer but also given the proliferation of men's continence products available to the lay public.

Given that IPT is caused by treatment of the prostate, it is by definition iatrogenic. As such, it is perhaps preventable or predictable. Understanding the nature of IPT is crucial for patients and clinicians during recovery and extended survivorship following prostate treatment. Clinicians benefit from being able to assess which patients will likely experience further symptom recovery versus those who will not. This allows clinicians to set clear and reasonable expectations regarding the short-, medium-, and long-term sequelae of IPT.

Although most clinicians are familiar with the more commonly known term "post-prostatectomy

incontinence," this Guideline uses the term "IPT", as a more inclusive term that covers the management of patients who have incontinence after undergoing treatment of localized prostate cancer and BPH. Evaluation of the patient, risk factors for IPT which should be discussed with all patients prior to treatment, assessment of the patient prior to intervention, and a stepwise approach to management are covered in this Guideline. Possible maneuvers to decrease rates of IPT, with specific focus placed on patients with SUI, are also explored. The multiple treatments that exist for patients with IPT are discussed and evaluated, including physical therapy, medications, and surgery. Algorithms for patient evaluation, surgical management, and device failure are provided for practitioners. While no clear convention for severity grading is accepted, for the purposes of this Guideline the following definitions are being used based on patient reported pads per day usage. Patient reported outcome measures, standing cough test, and daily pad weights can also be employed. Social continence is considered one or fewer pads per day that is tolerable to the patient.^{1, 2} Mild, moderate, severe incontinence is considered 1-2, 2-4, 5 plus pads per day reported by the patient, respectively.³⁻⁵

METHODOLOGY

The systematic review utilized to inform this Guideline was conducted by a methodology team at Mayo Clinic Evidence-Based Practice Research Program. Determination of the Guideline scope and review of the final systematic review to inform Guideline statements was conducted in conjunction with the Incontinence after Prostate Treatment Panel. The update search performed in 2023 was conducted by an independent methodologist.

Panel Formation

The IPT Panel was created in 2017 by the American Urological Association Education and Research, Inc. (AUAER). This Guideline was developed in collaboration with the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU). The Practice Guidelines Committee (PGC) of the American Urological Association (AUA) selected the Panel Chair, who in turn appointed additional panel members with specific expertise in this area, in conjunction with SUFU. Funding of the Panel was provided by the AUA with contributions from SUFU; panel members received no remuneration for their work.

In 2023, the Incontinence after Prostate Treatment Amendment Panel was created by the AUA to review new literature and provide updates herein.

Searches and Article Selection

A comprehensive search of several databases from 2000 to December 21st, 2017 was completed. Databases included Ovid MEDLINE Epub Ahead of Print, Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategy was designed and conducted by an experienced medical reference librarian with input from the Guideline methodologist. Controlled vocabulary supplemented with keywords was used to search for studies on IPT. The search was restricted to studies published in English and available in full text in the peer reviewed literature.

In 2023, the Incontinence after Prostate Treatment Guideline was updated through the AUA amendment process in which newly published literature is reviewed and integrated into previously published Guidelines. The methodologist searched Embase (1996 to June 2023),

EBM Reviews – Cochrane Central Register of Controlled Trials (May 2023), EBM Reviews – Cochrane database of Systematic Reviews (2005 to June 2023), Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily (2019 to June 2023).

Data Abstraction

Two reviewers independently selected studies and extracted data using standardized, pilot tested forms created in a systematic review software management system (Distiller SR, Evidence Partners, Ottawa, Canada). Disagreements were resolved by discussion between the two reviewers. Two main types of data were abstracted: baseline characteristics (study design, objective, inclusion and exclusion criteria, sample size, age, body mass index [BMI], intervention, period of follow up), and outcome data (number of patients who were incontinent and those with incontinence improvement, mean pads per day, quality of life [QoL], and complications).

Risk of Bias Assessment

The Newcastle Ottawa scale, which evaluates cohort selection, comparability and outcomes assessment, was used for non-randomized controlled trials (RCTs). The Cochrane risk of bias tool which evaluates random sequence generation, allocation concealment, blinding, and attrition was used for evaluation of RCTs.

Data Synthesis

When meta-analysis was appropriate, methodologists utilized the random-effects model *a priori* because of the anticipated heterogeneity across study populations and settings. Otherwise, outcomes were evaluated using narrative and descriptive approaches.

Determination of Evidence Strength

The categorization of evidence strength is conceptually distinct from the quality of individual studies. Evidence strength refers to the body of evidence available for a particular question and includes individual study quality in addition to consideration of study design; consistency of findings across studies; adequacy of sample sizes; and generalizability of samples, settings, and treatments for the purposes of the Guideline. Investigators graded the strength of evidence for key comparisons and outcomes

for each Key Question, using the approach described in the Agency for Healthcare Research and Quality Evidence-based Practice Center Methods Guide for Comparative Effectiveness and Effectiveness Reviews.⁶ Strength of evidence assessments were based on the following domains:

- Study limitations, based on the overall risk of bias across studies (low, medium, or high)
- Consistency of results across studies
- Directness of the evidence linking the intervention and health outcomes
- Precision of the estimate of effect, based on the number and size of studies and confidence intervals for the estimates (precise or imprecise)
- Reporting bias, based on whether or not the studies defined and reported primary outcomes and whether or not we identified relevant unpublished studies (suspected or undetected)

The AUA employs a 3-tiered strength of evidence system to underpin evidence-based guideline statements. **Table 1** summarizes the GRADE categories, definitions, and

how these categories translate to the AUA strength of evidence categories. In short, high certainty by GRADE translates to AUA A-category strength of evidence, moderate to B, and both low and very low to C.

The AUA categorizes body of evidence strength as Grade A (well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings), Grade B (RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings), or Grade C (RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data). By definition, Grade A evidence is evidence about which the Panel has a high level of certainty, Grade B evidence is evidence about which the Panel has a moderate level of certainty, and Grade C evidence is evidence about which the Panel has a low level of certainty.

TABLE 1: Strength of Evidence Definitions

| AUA Strength of Evidence Category | GRADE Certainty Rating | Definition |
|-----------------------------------|------------------------|---|
| A | High | <ul style="list-style-type: none"> • Very confident that the true effect lies close to that of the estimate of the effect |
| B | Moderate | <ul style="list-style-type: none"> • Moderately confident in the effect estimate • The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different |
| C | Low | <ul style="list-style-type: none"> • Confidence in the effect estimate is limited • The true effect may be substantially different from the estimate of the effect |
| | Very Low | <ul style="list-style-type: none"> • Very little confidence in the effect estimate • The true effect is likely to be substantially different from the estimate of effect |

AUA Nomenclature: Linking Statement Type to Evidence Strength

The AUA nomenclature system explicitly links statement type to body of evidence strength, level of certainty, magnitude of benefit or risk/burdens, and the Panel's judgment regarding the balance between benefits and risks/burdens (**Table 2**). **Strong Recommendations** are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is substantial. **Moderate Recommendations** are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is moderate. **Conditional Recommendations** are non-directive statements used when the evidence indicates that there is no apparent net benefit or harm or when the balance between benefits and risks/burden is unclear. All three statement types may be supported by any body of evidence strength grade. Body of evidence strength Grade A in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most patients in most circumstances, and that future research is *unlikely to change confidence*. Body of evidence strength Grade B in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most patients in most circumstances, but better evidence *could change confidence*. Body of evidence strength Grade C in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most patients in most circumstances, but better evidence *is likely to change confidence*. Body of evidence strength Grade C is only rarely used in support of a Strong Recommendation. Conditional Recommendations also can be supported by any evidence strength. When body of evidence strength is Grade A, the statement indicates that benefits and risks/burdens appear balanced, the best action depends on patient circumstances, and future research is *unlikely to change confidence*. When body of evidence strength Grade B is used, benefits and risks/burdens appear balanced, the best action also depends on individual patient circumstances, and better evidence *could change confidence*. When body

of evidence strength Grade C is used, there is uncertainty regarding the balance between benefits and risks/burdens, alternative strategies may be equally reasonable, and better evidence is *likely to change confidence*.

Where gaps in the evidence existed, the Panel provides guidance in the form of **Clinical Principles** or **Expert Opinions** with consensus achieved using a modified Delphi technique if differences of opinion emerged.⁷ A **Clinical Principle** is a statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature. **Expert Opinion** refers to a statement, achieved by consensus of the Panel, that is based on members' clinical training, experience, knowledge, and judgment for which there is no evidence.

Peer Review and Document Approval

An integral part of the Guideline development process at the AUA is external peer review. The AUA conducted a thorough peer review process to ensure that the document was reviewed by experts in the treatment of IPT. In addition to reviewers from the AUA PGC, Science and Quality Council (SQC), and Board of Directors (BOD), the document was reviewed by representatives from AUA and SUFU as well as external content experts. Additionally, a call for reviewers was placed on the AUA website from January 14 to 28, 2019 to allow any additional interested parties to request a copy of the document for review. The Guideline was also sent to the Urology Care Foundation to open the document further to the patient perspective. The draft Guideline document was distributed to 49 external peer reviewers. All peer review comments were blinded and sent to the Panel for review. In total, 33 reviewers (9 AUA PGC, SQC, and BOD reviewers; 22 external reviewers; and 2 public reviewers) provided comments. At the end of the peer review process, a total of 476 comments were received. Following comment discussion, the Panel revised the draft as needed. Once finalized, the Guideline was submitted for approval to the AUA PGC, SQC and BOD as well as the governing bodies of SUFU for final approval.

TABLE 2: AUA Nomenclature Linking Statement Type to Level of Certainty, Magnitude of Benefit or Risk/Burden, and Body of Evidence Strength

| Evidence Grade | Evidence Strength A (High Certainty) | Evidence Strength B (Moderate Certainty) | Evidence Strength C (Low Certainty) |
|---|--|---|--|
| Strong Recommendation (Net benefit or harm substantial) | -Benefits > Risks/Burdens (or vice versa) -Net benefit (or net harm) is substantial -Applies to most patients in most circumstances and future research is unlikely to change confidence | -Benefits > Risks/Burdens (or vice versa) -Net benefit (or net harm) is substantial -Applies to most patients in most circumstances but better evidence could change confidence | -Benefits > Risks/Burdens (or vice versa) -Net benefit (or net harm) appears substantial -Applies to most patients in most circumstances but better evidence is likely to change confidence (rarely used to support a Strong Recommendation) |
| Moderate Recommendation (Net benefit or harm moderate) | -Benefits > Risks/Burdens (or vice versa) -Net benefit (or net harm) is moderate -Applies to most patients in most circumstances and future research is unlikely to change confidence | -Benefits > Risks/Burdens (or vice versa) -Net benefit (or net harm) is moderate -Applies to most patients in most circumstances but better evidence could change confidence | -Benefits > Risks/Burdens (or vice versa) -Net benefit (or net harm) appears moderate -Applies to most patients in most circumstances but better evidence is likely to change confidence |
| Conditional Recommendation (Net benefit or harm comparable to other options) | -Benefits = Risks/Burdens -Best action depends on individual patient circumstances -Future Research is unlikely to change confidence | -Benefits = Risks/Burdens -Best action appears to depend on individual patient circumstances -Better evidence could change confidence | -Balance between Benefits & Risks/Burdens unclear -Net benefit (or net harm) comparable to other options -Alternative strategies may be equally reasonable -Better evidence likely to change confidence |
| Clinical Principle | a statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature | | |
| Expert Opinion | a statement, achieved by consensus of the Panel, that is based on members' clinical training, experience, knowledge, and judgment for which there may or may not be evidence in the medical literature | | |

In 2024, as a part of the amendment process, the AUA conducted a thorough peer review process. A call for peer reviewers was posted on February 7th, 2024 and the draft Guideline document was distributed to 85 peer reviewers, 32 of whom submitted comments. The Amendment Panel reviewed and discussed all submitted comments and revised the draft as needed. Once finalized, the Guideline was submitted to the AUA PGC, SQC, and BOD for final approval in addition to the approval bodies of collaborators SUFU and the Society of Genitourinary Reconstructive Surgeons (GURS).

GUIDELINE STATEMENTS

PRE-TREATMENT

1. Clinicians should inform patients undergoing localized prostate cancer treatment of all known factors that could affect continence. (Moderate Recommendation; Evidence Level: Grade B)

Radical prostatectomy and radiation therapy for prostate cancer are both associated with urinary incontinence after treatment,^{8, 9} with urinary incontinence more common following surgery than radiation. Ten-year data from the CEASAR trial (NCT01326286) shows 14% to 25% of men who had prostatectomy reported bothersome leakage compared to 4% to 11% in the external beam radiation group.⁹ Data suggest similar rates of leakage across types of radiotherapy.¹⁰ High intensity focused ultrasound (HIFU) and cryotherapy can also lead to incontinence following treatment.^{11, 12} Some data suggest that the differential impacts of the therapies on incontinence diminishes over time and is similar at 15 years post treatment.¹³ While surgery patients experience more incontinence initially, the impacts of radiation increase over time, and cases of adjuvant radiation may be particularly harmful to urinary health as SUI and urge incontinence is common.¹⁴

Many patient and surgical based factors have been evaluated to determine their impact on recovery of continence after RP. Younger patient age, smaller prostate size, and longer membranous urethral length (measured by MRI) have been consistently associated with improved recovery of continence after RP. A meta-analysis of studies evaluating age as a risk factor of IPT found that increasing patient age at the time of RP increases risk of incontinence.¹⁵⁻²⁰ Similarly, increasing prostate size results in increased odds of IPT,^{16-18, 21-29}

while increasing membranous urethral length results in decreased risk.^{16-18, 21, 24, 30-32} Although each of the above are risk factors, their relationship to IPT is complex and nonlinear. Predictive models should account for this nonlinearity and are best represented as nomograms.²¹

Surgical approaches do not seem to impact rates of IPT; in particular, open RP has similar rates of urinary incontinence as robot-assisted RP.^{33, 34} There is no current evidence that any surgical maneuvers, beyond bilateral neurovascular bundle preservation, results in improved continence recovery at 12 months.³⁵⁻³⁸ Some studies support early return of continence for Retzius sparing RP, although continence rates at 12 months are similar to other techniques.^{39, 40} Men receiving bilateral neurovascular bundle preservation were 26% more likely to be continent at six months compared to men who did not;⁴¹⁻⁴⁶ however, surgeons should base the degree of nerve sparing on the features of the cancer rather than pre-operative potency. Men with poor pre-operative potency still benefit from nerve sparing in terms of recovery of continence.^{47, 48}

BMI may impact IPT in the short-term; however there is little evidence that it is a risk factor for incontinence after RP at one year.^{16-18, 21, 23-29}

2. Clinicians should counsel patients regarding the risk of sexual arousal incontinence and climacturia following localized prostate cancer treatment. (Strong Recommendation; Evidence Level: Grade B)

Urologists should inform patients of the risks of sexual arousal incontinence and climacturia. Sexual arousal incontinence is characterized by the inadvertent loss of urine during sexual arousal, foreplay, and/or masturbation. Climacturia (also known as orgasm-associated urinary incontinence) is the involuntary loss of urine at the time of orgasm. This can occur following RP, with or without adjuvant RT, and can even occur in those treated with RT alone. While precise prevalence has not been well-established, several studies report an incidence of sexual arousal incontinence and climacturia following prostate cancer surgery ranging from 20% to 93%, with most reporting an overall rate close to 30%.⁴⁹ Rates of climacturia after RT are lower (4% to 5.2%), while other ejaculatory dysfunction, such as anejaculation, is common after radiation (11% to 72%).^{50, 51}


The pathophysiology of climacturia is not completely understood. The mechanism is thought to relate to removal of the internal sphincter during RP, which is exacerbated by prior transurethral resection of the prostate (TURP). Bladder contraction at the time of orgasms with some degree of external sphincter insufficiency is thought to result in leakage during orgasm.⁵²

Although climacturia and SUI are not mutually exclusive, there is some overlap between the conditions. In patients with climacturia, 30% do not experience SUI; conversely, 30% of patients with SUI do not report climacturia.⁵¹ While the risk factors for climacturia are not as well defined as those for SUI, the main risk factor is time since surgery (shorter time from surgery is associated with a higher rate of leakage). Additionally, there appears to be a faster recovery of continence during sexual activity following robotic RP compared to open or pure laparoscopic RP.⁵³ Improvement can be expected throughout the postoperative period, but it can take several years to resolve, and typically persists in one-third of patients.^{49, 54} Other risk factors include prior TURP, as well as shorter functional urethral and penile length following RP. It does not appear that age, pre-operative erectile function, or nerve sparing status significantly affect the risk of sexual arousal or orgasm-related incontinence.⁵¹

3. Clinicians should inform patients undergoing radical prostatectomy that incontinence is expected in the short-term and generally improves to near baseline by 12 months after surgery but may persist and require treatment. (Strong Recommendation; Evidence Level: Grade A)

A commonly accepted definition of urinary continence is not requiring a pad or protective device to stay dry (pad-free).⁵⁵ Most men undergoing RP are not continent (pad-free) at the time of catheter removal and should be informed that continence is not immediate.²⁰ Continence after RP improves with time, and most men achieve continence within 12 months of surgery.²⁰ Men considering RP should be provided with reasonable expectations regarding recovery of continence. Because incontinence is expected in the early phase after surgery, conservative management with regular follow-up during the first year after surgery is recommended to assess patient progress. The spectrum of improvement over time based on procedure is shown in **Figure 1**.

Figure 1



RARP: Robotic-assisted radical prostatectomy
 RALP: Robot-assisted laparoscopic prostatectomy
 RRP: Retropubic radical prostatectomy

4. Prior to radical prostatectomy, clinicians may offer patients pelvic floor muscle exercises or pelvic floor muscle training. (Conditional Recommendation; Evidence Level: Grade C)

Voluntarily activating the pelvic floor muscles through an exercise program prior to RP is a common practice. Exercises for the pelvic floor muscle are easier to learn in the pre-operative period since mastery can be difficult postoperatively given muscle inhibition, sensory changes, urinary incontinence, and surgical pain.⁵⁶ Typical preliminary goals of a preoperative program include proper patient education regarding pelvic floor muscle anatomy, physiology, awareness, and motor control, which maximize the effectiveness of exercises.

Pelvic floor muscle exercise (PFME) is defined in this Guideline as an exercise program specific to the pelvic floor muscle group that is self-guided as a home exercise program only. The patient may have learned the program through patient education literature or with a single basic instruction session from an appropriate practitioner. Pelvic floor muscle training (PFMT) is defined as a training program specific to the pelvic floor muscle group that is practitioner guided. Typically, PFMT will consist of individualized pelvic floor muscle awareness training using verbal, tactile, and/or visual feedback along with a

home based PFME program to be progressed during follow-up visits with the practitioner.

Seven trials met inclusion criteria regarding the effectiveness of a pre-operative PFMT program improving post-prostatectomy continence. The robustness of the recommendation is limited by heterogeneous methods of evaluation and comparison among the different studies.

The PFMT methods utilized to optimize pelvic floor muscle awareness included verbal cues,⁵⁷⁻⁵⁹ tactile cues,^{57, 59, 60} visualization of penile movement,⁵⁹ surface electromyography biofeedback,^{58, 60, 61} pressure biofeedback,⁶² and transabdominal ultrasound imaging.⁵⁷ Overall, these methods successfully assisted patients in isolating and contracting their pelvic floor muscles. However, it is not clear whether they are truly necessary or which methods are more beneficial.

To allow for neuromuscular adaptation, preoperative PFMT should be started three to four weeks prior to surgery.⁵⁷⁻⁶⁰ However, the Panel can neither recommend the optimal time frame for initiation of pre-operative PFMT, nor the ideal intensity of the program due to reported variability in start times found in the literature.⁶¹⁻⁶³ The methods, dosage, and level of follow-up for PFMT and PFME in the post-operative period also varied among trials.

The benefit of starting pre-operative PFMT is not consistent in the outcome data. In one view, pre-operative PFMT has been shown to be effective in hastening continence recovery after surgery,^{57, 59, 62, 63} while other efforts have failed to demonstrate a beneficial effect on continence.^{58, 60} All trials varied with respect to assigned PFMT/PFME regimens, definitions of continence, and length of follow-up. It is important to note that formal PFMT is not harmful, and the potential benefits clearly outweigh any potential risks and likely decrease regret.⁶⁰

5. Clinicians should inform patients undergoing radical prostatectomy or transurethral resection of the prostate after radiation therapy of the high rate of urinary incontinence following these procedures. (Moderate Recommendation; Evidence Level: Grade C)

TURP

TURP following brachytherapy or external beam radiation has been associated with incontinence rates of up to 70%.^{64, 65} The urethral fibrosis developing from radiation-

related progressive endarteritis decreases the functional capabilities of the external sphincter. Even in the absence of direct damage to the sphincter, adjacent surgical cautery or laser energy further compromises sphincter function. The need for subsequent resections, patient age, and pre-TURP urgency is correlated with higher rates of incontinence.⁶⁶

There is little to no published evidence discussing post-TURP outcomes with patients who have undergone other forms of local therapy such as HIFU and cryotherapy. However, it is the opinion of this Panel that these patients have high risks of incontinence similar to post-TURP radiated patients.

Salvage Prostatectomy

Regardless of the initial form of non-operative therapy or the operative approach, salvage RP is associated with high rates of urinary incontinence rates (ranging from 20% to 70%) for both open and robotic techniques compared to standard RP.⁶⁷⁻⁷³

Patients undergoing TURP or salvage RP after primary non-surgical treatment for prostate cancer who seek long-term continence should be informed that they may require an artificial urinary sphincter (AUS).

POST-PROSTATE TREATMENT

6. In patients who have undergone radical prostatectomy, clinicians should offer pelvic floor muscle exercises or pelvic floor muscle training in the immediate post-operative period. (Moderate Recommendation; Evidence Level: Grade B)

Short-term PFMT may be offered to patients who are not able to perform self-directed PFME with appropriate quality and who request additional interventions to hasten the recovery of continence after RP. PFME after catheter removal has been shown to improve time-to-achieving continence compared to control groups in RCTs⁷⁴ and should be offered to all patients after RP upon removal of the urethral catheter. Those patients who are committed to a progressive PFMT or PFME program can expect an earlier return to continence than those who are not.⁶¹ The timeframe for this early continence recovery after RP can be as early as three^{61, 63, 75-77} to six months.⁷⁸ However, longer term assessment suggests that overall continence rates at one year remain similar between men who underwent PFME or PFMT and those who did not.⁷⁹

Long-term assessment is skewed because of highly heterogeneous data and continence rates between men treated with PFME/PFMT are similar to those not treated (57% with urinary incontinence in intervention group versus 62% in control group; risk ratio [RR]: 0.85 at 12 months; 95% confidence interval [CI]: 0.60 to 1.22).⁷⁹ Overall these data suggest that if performed in the early post-operative period, PFME or PFMT improve time to continence (thus improving QoL) but not overall continence at 12 months.

7. In patients with bothersome stress urinary incontinence after prostate treatment, clinicians may offer surgery as early as six months if incontinence is not improving despite conservative therapy. (Conditional Recommendation; Evidence Level: Grade C)

While almost all patients have reached their maximum improvement by 12 months, most patients with severe SUI will show no significant improvement after six months and may be candidates for early intervention. A review of the data indicates that 90% of patients will achieve continence at six months after robotic-assisted laparoscopic prostatectomy and only an additional 4% of patients will gain continence afterwards.^{20, 80-85} Such data highlight that symptom improvement often plateaus earlier than one year. Patients who report a lack of symptom improvement or those experiencing more severe incontinence at six months may be offered early treatment in the form of surgical interventions with such a treatment decision made using a shared decision-making model.

8. In patients with bothersome stress urinary incontinence after prostate treatment despite conservative therapy, clinicians should offer surgical treatment at one year post-prostate treatment. (Strong Recommendation; Evidence Level: Grade B)

Timing of treatment should be optimized to restore QoL as soon as possible without over-treatment. The natural history of incontinence after prostate surgery shows that the clear majority of patients will reach their maximum improvement by 12 months with minimal to no improvement afterwards. While cumulative data^{20, 80-85} has shown that 94% of patients achieve continence by 12 months,^{83, 86} patients followed for 24 months after robotic-assisted laparoscopic prostatectomy revealed that only an additional 1% of patients had continued improvement

from 12 to 24 months. Withholding surgical treatment after 12 months is unlikely to result in improved patient symptoms and will delay restoration of continence. Patients who are eager to become dry and whose symptom improvement has reached a plateau may desire surgical treatment earlier than one year, and shared decision-making is key in initiating this intervention. Conversely, treatment should be offered with caution in patients who are displaying symptom improvement.

EVALUATION OF INCONTINENCE AFTER PROSTATE TREATMENT

9. Clinicians should evaluate patients with incontinence after prostate treatment with history, physical exam, and appropriate diagnostic modalities to categorize type and severity of incontinence and degree of bother. (Clinical Principle)

There is no formal evidence regarding the effects of history and physical exam on outcomes of IPT treatments; however, there is universal agreement that taking a history and performing a physical examination should be the first step in the assessment of anyone with urinary incontinence.⁸⁷ There is strong evidence that a history of pelvic RT^{88, 89} is associated with the severity of incontinence, especially stress incontinence,^{90, 91} after prostate surgery.

The Panel believes that before treating IPT, it is critical to categorize the type of incontinence (stress, urgency, mixed) and the severity and degree of bother of incontinence. The status of prostate cancer also should be known, particularly for men who are candidates for salvage RT, which may impact efficacy of continence treatment.

History is the first step in determining the type of incontinence, which is important because treatments for SUI (caused by sphincteric insufficiency) and urgency incontinence (caused by bladder dysfunction) are very different. In cases of mixed incontinence, it can be important to determine which component is more prevalent and bothersome, though many investigators feel that treatment outcomes for urgency incontinence may be difficult to determine in the face of significant sphincteric insufficiency.

History should focus on characterization of incontinence (stress or activity related versus urgency related), the severity of incontinence, the progression or resolution of incontinence over time, and degree of bother. Specifically, patients should be questioned on which activities causes incontinence. Increases in abdominal pressure such as that caused by straining, walking, cough, and exercise are suggestive of SUI, while the sudden compelling desire to void that is difficult to defer and results in leakage indicates urgency incontinence.⁹² Presence of incontinence while asleep as well as nocturia are also important to note, because this may indicate urgency urinary incontinence or severe SUI. Confirmation of SUI can often be determined by history or physical exam alone; however, there are times when a clinician may choose advanced testing such as urodynamic studies (UDS).

The severity of incontinence (i.e., volume lost over time) is important to know, especially in the case of sphincteric insufficiency as some treatments (e.g., male slings), clearly have inferior results in severe incontinence. Incontinence severity can be determined by history, or more objectively, by pad testing. It has been shown that careful questioning regarding pad number, size, and degree of wetness correlates well with pad weights and effect on QoL.³ However, there may be times when a formal one-hour or 24-hour pad test may be helpful in determining incontinence severity.^{3, 93} The Panel agrees that it is important to determine the degree of bother of incontinence and effect on QoL since this will help to determine the type of initial treatment, or no treatment, and guide counselling through a shared decision-making model.

10. In patients with urgency urinary incontinence or urgency predominant mixed urinary incontinence, clinicians should offer treatment options per the American Urological Association Overactive Bladder Guideline. (Clinical Principle)

The occurrence of urinary frequency, urgency, and urgency urinary incontinence is common after prostate treatment.⁹⁴⁻⁹⁷ A review of urinary symptoms after RP reveals that 29% of patients will develop one or more symptoms, with 19% developing urinary urgency and 6% complaining of urgency incontinence.⁹⁴ Clinicians should be aware of the prevalence of overactive bladder (OAB), which has been described as high as 48%⁹⁸ and specifically assess for symptoms after prostate treatment.

Evaluation and treatment can be initiated at any time post-prostate treatment and should follow the Overactive Bladder in Adults: AUA/SUFU Guideline.^{99, 100} The presence of urgency urinary incontinence should not exclude a patient from surgical treatment of his bothersome SUI.

11. Prior to surgical intervention for stress urinary incontinence, clinicians should confirm stress urinary incontinence by history, physical exam, or ancillary testing. (Clinical Principle)

Prior to surgical intervention for SUI, clinicians should be certain that a patient truly has sphincteric insufficiency as a cause for his incontinence. History of SUI has a 95% positive predictive and 100% negative predictive value for the presence of SUI on UDS.¹⁰¹ Evidence has not definitely shown whether or not the objective demonstration of SUI predicts surgical outcomes after prostate cancer treatment. The AUA/SUFU Guideline on the Surgical Management of Female Stress Urinary Incontinence states that the objective demonstration of SUI should be confirmed prior to surgical management (based on Panel consensus).¹⁰² Similarly, a recent International Continence Society consensus Panel on AUS recommended that every effort should be made to objectively confirm the presence of SUI prior to AUS placement.¹⁰³ Clinicians should take all reasonable measures to demonstrate SUI on physical exam with or without provocative testing such as bending, shifting position, or rising from seated to standing position. Stress pad testing can also be performed. Finally, if there is any doubt as to whether the patient has SUI, UDS may be performed. Examples of this may be when the patient has significant mixed incontinence and stress incontinence is not demonstrated, in cases where impaired compliance is suspected and incontinence could be related to high storage pressures without urgency, or if overflow incontinence is suspected. In the case of the latter, a post-void residual (PVR) may be helpful to rule out significant retention of urine.

The presence of microscopic hematuria may warrant additional evaluation with upper tract imaging and cystoscopy. The assessment of PVR may alert the physician to the potential for incomplete bladder emptying; however, the reliability of a single elevated PVR value for predicting emptying dysfunction remains in question, just as a single low PVR value does not rule out the presence of incomplete emptying. Second, the

threshold value of a significant PVR is similarly undefined. Finally, a persistently elevated PVR does not characterize the cause of impaired emptying, but rather indicates the need for further evaluation. Additionally, an elevated PVR in the presence of SUI may impact patient counseling regarding surgical interventions and patient expectations. Elevated PVR may be an indication of detrusor underactivity or obstruction (e.g., urethral stricture or bladder neck contracture [BNC]) and thus may prompt further diagnostic evaluation such as uroflowmetry, cystoscopy, or multichannel UDS.

12. Clinicians should inform patients with incontinence after prostate treatment of management options for their incontinence, including surgical and non-surgical options. (Clinical Principle)

Prior to engaging in any active or invasive form of therapy, patients must be made aware of the conservative options for management of urinary incontinence, such as absorbent pads, penile compression devices (clamps), and catheters. These alternatives may be utilized while engaging in PFME/PFMT, considering future options, waiting an appropriate time before surgical intervention, or as an indefinite form of management. Those patients who are candidates for surgical intervention in the future require assistance in handling ongoing leakage in a comfortable, reliable, and cost-efficient manner.¹⁰⁴

In IPT management, the conservative approach is first-line to control urinary leakage post catheter removal. Absorbent pads, which are available in an array of forms and sizes, are the primary tool of urinary containment. Penile compression devices can be used independently and as an adjunct to reduce daily absorbent product usage. Catheters (condom and urethral), may be necessary in patients with high volume pad usage suffering from skin excoriation, dermatitis, and cellulitis due to urinary leakage.

Absorbent Products – Liners, Guards, Briefs, Underwear

Most patients will start with absorbent pads and make adjustments in type based on the severity of leakage.¹⁰⁴ In general, milder incontinence is managed satisfactorily with shields or lower density guards, while severe incontinence requires briefs or underwear with or without inserts to prevent accidents. From a cost perspective, briefs and underwear systems have been demonstrated to be more effective than pads.¹⁰⁵ Thus, the patient should

be advised along these lines if they wish to continue wearing pads as their primary mechanism for urinary containment.

In the individual patient, absorbent products alone may constitute a long-term management strategy. However, it has been demonstrated that the use of even one pad per day is a source of bother and decreased patient satisfaction.¹⁰⁶ Additionally, the use of pads may be associated with skin irritation and dermatitis, especially in the intertriginous areas. In those who need to use more than several pads or garments per day, financial considerations may influence the ability to change pads in a timely fashion. Therefore, it is important to ensure that the patient is utilizing the most effective product based on their degree of incontinence.

Occlusive Devices (Clamps)

Occlusive devices may function as a stand-alone therapy for incontinence or as an adjunct to absorbent products. Combination therapy between the two types of devices, such as pads and clamps together, decreases the number of pads required during active periods with a resultant decrease in incontinence products expenditure. Patients must be instructed to release the clamp every two hours to allow for circulation regardless of the need to void. The clamp should not be left on the phallus overnight due to the risks of constant pressure. While successful in decreasing urine loss, compressive devices are associated with decreased penile Doppler flow.¹⁰⁷ Mechanical compression devices are not suitable for patients with memory deficits, poor manual dexterity, impaired sensation, or a significant component of OAB.

Catheters (Condom, Urethral, and Suprapubic)

Patients with severe or total incontinence may resort to a catheter and drainage system as the best method to obtain complete control of urinary incontinence. This form of management is also advantageous when the number or frequency of absorbent product changes is disruptive and/or financially prohibitive. Condom type catheters or urinary sheaths are an effective method of urinary containment for men with severe incontinence. In comparison to compressive devices, condom catheter systems are acceptable for patients with any degree of urge incontinence. Theoretically, this approach would also be superior to urethral catheterization due to the avoidance of mechanical bladder irritation. However, this management is unsuitable for patients with a retractile

phallus, skin excoriation, concomitant urethral stricture, poor manual dexterity, or a large glans/narrow phallus configuration.¹⁰⁸ In the appropriate patient, external catheters have been demonstrated to be superior to absorbent products in patient satisfaction. However, the success of a condom catheter is wholly dependent on proper sizing. The condom or sheath varies based on the material (latex or silicone), length of adhesive surface, circumference, and overall length.¹⁰⁹ Urethral catheter drainage is a decision of last resort in a patient who is unsuitable for alternative management. Suprapubic catheter drainage is not a solution for the patient with severe intrinsic sphincter deficiency, as urethral leakage will persist.

13. In patients with incontinence after prostate treatment, clinicians should discuss risk, benefits, and expectations of different treatments using the shared decision-making model. (Clinical Principle)

The treatment of IPT can be a complex process involving numerous risks and benefits for the patient. Given these inherent complexities, providers should engage patients in shared decision-making during evaluation, treatment, and follow-up. Shared decision-making is a process in which providers and patients work together to make decisions about tests, interventions, and care plans.¹¹⁰ Shared decisions are made based on clinical evidence that takes into account the risks and benefits and is teamed with patient preferences and values. The approach is predicated on two principles: 1) Patients provide accurate information and can and will participate in the medical decision-making process by asking questions and expressing opinions about their treatment options. 2) Providers will honor patient preferences for goals and treatment and use them to guide recommendations. Evidence suggests that patient participation improves patient satisfaction. Shared decision-making produces better health outcomes by decreasing anxiety, promoting faster recovery, and improving compliance.¹¹¹⁻¹¹⁴

14. Prior to surgical intervention for stress urinary incontinence, clinicians should perform cystourethroscopy to assess for urethral and bladder pathology that may affect outcomes of surgery. (Expert Opinion)

The presence of urethral pathology (e.g., stricture, BNC, urethral lesions) may affect the outcome of surgery for

SUI; therefore, some assessment to rule out significant urethral pathology is recommended. The gold standard for this would be a visual assessment of the urethra, including the membranous urethra, prostatic urethra (if present), and bladder neck with cystourethroscopy. Cystourethroscopy has also been recommended prior to placement of transobturator slings to assess urethral function (patients should have visual voluntary contraction of the external sphincter), and luminal closure of the urethra should be demonstrated with bulbar compression and elevation (repositioning test).¹¹⁵ However, success of the procedure has not been shown to be dependent on these findings in any controlled study. In addition to an evaluation of the urethra, sphincter and bladder neck, pre-operative cystourethroscopy can assess the bladder for any pathology that could affect the decision to perform surgery for stress incontinence. There is, however, no evidence that patients who undergo pre-operative cystourethroscopy have better outcomes for AUS or sling compared to those who do not. With this in mind, the International Continence Society consensus panel of AUS in 2015 stated that preoperative cystourethroscopy should be performed whenever feasible as unrecognized urethral and bladder neck pathology can significantly complicate AUS placement. Unrecognized significant pathology may result in aborting AUS placement in favor of a staged approach. Having this information preoperatively is beneficial to the patient and the surgeon to clarify expectation and maximize patient satisfaction.¹⁰³

In cases where pre-operative cystourethroscopy is not performed, it may be done at the start of the AUS or sling implantation before any incision is made. In such cases, patients should be made aware of the potential consequences and the possibility of aborting an AUS or sling insertion if significant urethral or bladder pathology is discovered.

15. Clinicians may perform urodynamic testing in patients prior to surgical intervention for stress urinary incontinence in cases where it may facilitate diagnosis or counseling. (Conditional Recommendation; Evidence Level: Grade C)

UDS allows for a precise evaluation of lower urinary tract function with respect to storage and emptying. It can aid in determining if IPT is caused by sphincter dysfunction, bladder dysfunction, or a combination of both, and also assess bladder contractility and the presence of bladder

outlet dysfunction. Thus, UDS can be helpful in situations where this information is not apparent from history, physical, or simple testing. UDS is not required before surgical intervention for IPT unless the clinician is in doubt of the diagnosis or it is felt that patient counseling will be affected. Unlike for the surgical treatment of SUI in women, there are no controlled studies that assess the value of UDS versus no UDS in men with SUI prior to surgery. In women with uncomplicated SUI, studies show UDS added no value over simple office evaluation,¹¹⁶ and there is no advantage to UDS-based treatment of abnormalities other than stress incontinence.¹¹⁷ There are a number of retrospective cohort studies that have shown that the presence of UDS abnormalities of storage (e.g., detrusor overactivity, impaired compliance, small cystometric capacity) do not affect outcomes of AUS or sling surgery in men with SUI.¹¹⁸⁻¹²¹ Similarly, detrusor over-activity found on UDS has not been shown to negatively impact sling outcomes in men with SUI after prostate treatment.¹²² In addition, abdominal leak-point pressure has not been shown to affect outcomes of AUS.¹¹⁹ Furthermore, abdominal leak-point pressure does not correlate well with the degree of urinary incontinence, as determined by the 24-hour pad test.¹²³ Pre-operative UDS may have a role in patient counseling (e.g., which patients may need further treatment of OAB symptoms post implant); however, patient selection for this reason is not well characterized. Finally, if the clinician is unsure of how prevalent sphincteric versus bladder affecting incontinence, or if there is unexplained poor bladder emptying, then UDS may be helpful in providing that additional information.

It is also important that the catheter be removed and stress testing repeated in men with suspected SUI who do not demonstrate stress incontinence with a catheter in place. It has been shown that up to 35% of men with post-prostatectomy SUI will not demonstrate SUI with a catheter in place.¹²⁴ This may be due to some scarring at the site of the anastomosis. In such cases, even a small catheter can occlude the urethra and prevent stress leakage. Also, if obstruction is suspected based on UDS criteria, a uroflow should be repeated without the catheter in place due to the possible obstructive effects of the catheter.

The most concerning and potentially most dangerous UDS finding is poor bladder compliance. This finding, however, is rare in IPT, even in patients who have had

RT.¹²⁵ UDS likely has the highest yield for poor compliance in patients with severe radiation cystitis or those who have advanced neurogenic lower urinary tract dysfunction. Patients with significantly elevated storage pressures can be treated primarily (if no stress incontinence) with anticholinergics or onabotulinumtoxin A to lower such pressures. UDS then can be repeated to document adequate reservoir function. For patients with poor compliance and SUI, the observation that untreated poor bladder compliance did not worsen the AUS continence outcomes must be viewed with caution. It is well known that increasing outlet resistance could potentially expose the upper tracts to even higher intravesical pressures as compliance worsens.¹²⁶ Such patients can be treated with anticholinergics or onabotulinumtoxin A and storage pressure can be rechecked prior to treating SUI. Alternatively, periodic upper tract imaging and/or UDS can be done post- SUI surgery (sling or AUS) to follow “at risk” patients. While the risk damage to the upper tracts in pediatric patients with myelomeningocele is well documented,¹²⁷ it is not known if poor bladder compliance and an uncorrected storage pressure are absolute contraindications to SUI surgery in IPT patients. However, the Panel believes that when such patients are identified, they should be carefully followed to avoid upper tract decompensation.

TREATMENT OPTIONS

16. In patients seeking treatment for incontinence after radical prostatectomy, clinicians should offer pelvic floor muscle exercises or pelvic floor muscle training. (Moderate Recommendation; Evidence Level: Grade B)

IPT is caused by damage to the voluntary urethral sphincter. Both injury to striated muscle and nerve fibers of the rhabdo-sphincter can lead to IPT. PFMT is thought to support muscle strength and enhance blood flow to the sphincter to promote healing.⁷⁸ PFMT is a safe treatment with minimal side-effects that is readily accepted by patients and provides them with an opportunity to participate in, and have some control over, their health outcomes. Relative downsides to PFMT include time and effort needed by the patient and health care team, and cost of repeated visits, depending on the intensity of the program.^{128, 129}

There are numerous RCTs that suggest benefit of undertaking PFMT^{61, 63, 75, 128, 130-132} while other studies did

not show benefits.^{128, 129} Trials differ on the regimen of PFMT employed, with some including biofeedback or electrical stimulation, the amount of caregiver contact,^{76, 78} and whether or not the therapy was before or after surgery.^{61, 133-135} Further, trials lack a common urinary incontinence definition, making comparison more challenging.

Although PFMT and PFME may both be beneficial in restoring pelvic floor muscle function to assist with continence recovery, there is some evidence that PFMT may be preferred over self-directed PFME potentially due to the practitioner guided support and follow-up instruction offered with PFMT.^{76, 78, 131}

17. Clinicians should discuss the option of artificial urinary sphincter with patients who are experiencing mild to severe stress urinary incontinence after prostate treatment. (Strong Recommendation; Evidence Level: Grade B)

Multiple studies have demonstrated that AUS produces long-term continence and high patient satisfaction in men with any level of bothersome SUI.^{44, 136-145} AUS should be discussed as a treatment option when surgical treatments are being considered.¹⁴³ Patients should be informed regarding inherent risks of AUS placement including persistent leakage, mechanical failure, erosion, and infection.^{139, 140, 143}

In one study of AUS outcomes with two-year follow-up, complete continence was achieved in 20%, 55% had leakage of a few drops daily, and 22% had leakage of less than a teaspoon.¹³⁹ The patients were highly satisfied, with 92% reporting they would do the surgery again, and 96% willing to recommend the surgery to a friend.¹³⁹ In another study with follow-up of 2 to 11 years, a significant pad reduction was seen after AUS placement (4.0 to 0.6 pads per day).¹⁴⁰

18. Prior to implantation of artificial urinary sphincter, clinicians should ensure that patients have adequate physical and cognitive abilities to operate the device. (Clinical Principle)

While AUS is the most predictable and reliable treatment for SUI after prostate treatment, it is important to remember that it is a mechanical device and that current versions of AUS require manual dexterity and cognitive ability in order for the patient to use it properly. Patients must demonstrate the cognitive ability to know when, where, and how to use the device. Furthermore, there

should be some assurance that patients can physically pump a device that is in a normal position in the scrotum. There are no uniform ways to demonstrate such dexterity, but a simple demonstration of strength in the fingers and the ability to squeeze the pump between the index finger and thumb should be minimal requirements.

19. In patients who select artificial urinary sphincter, clinicians should preferentially utilize a single cuff perineal approach. (Moderate Recommendation; Evidence Level: Grade C)

The traditional placement of AUS has been a single cuff via perineal incision.¹⁴⁶ The introduction of new techniques such as the transverse scrotal incision and tandem cuff placement have been evaluated to be inferior in non-randomized studies and should not be the standard of care for the customary AUS patient.^{1, 105, 147-149}

While AUS placement is feasible via a transverse scrotal incision,¹⁰⁵ comparative studies indicate inferior outcomes. A review of complication rates between perineal and scrotal incisions revealed an increase complication rate requiring short-term explantation in 9% versus 19% when comparing the perineal versus transverse scrotal incisions, respectively.¹⁴⁷ In a multi-center cohort study, the transverse scrotal approach demonstrated decreased completely dry rates, increased need for revision surgery due to continued incontinence, and a decrease in number of socially continent patients (≤ 1 pad/day).¹ Taken together, these studies indicate that the transverse scrotal approach has a decrease in efficacy, likely due to a more distal cuff placement, along with an increase in complications and need for revision surgery.

In regard to placement of a tandem cuff compared to a single cuff placement, a review of the data indicates equivalent continence outcomes but with an increased risk of complications in the tandem cuff group.^{148, 149} In a cohort of 124 tandem cuff and 57 single cuff patients, outcomes indicated equal pad weight and total number of daily pads between the two groups, but the tandem cuff group had a 17% risk of explant at 48 months compared to 4% for the single cuff group.¹⁴⁸ In another cohort, overall dry rate and daily pad use between the two groups was similar, but the tandem cuff group had 12 additional surgeries related to complications versus seven in the single cuff group.¹⁴⁹

These comparative studies continue to support the traditional surgical approach of a single cuff via perineal approach as the standard technique that should be used. Furthermore, it is important to note that meticulous sterile technique needs to be employed during this approach, preoperative antibiotics should be always given to cover skin flora as per the AUA Antimicrobial Prophylaxis Best Practice Statement,¹⁵⁰ and surgeons must be able to select the appropriate cuff based on intraoperative measurements, fill the components of the AUS with fluid, connect the tubing to make a watertight system, and test the AUS. If an intraoperative urethral injury is identified during implantation of an AUS, the procedure should be abandoned and subsequent implantation should be delayed.

20. Clinicians should discuss the option of male slings with patients as treatment options for mild to moderate stress urinary incontinence after prostate treatment. (Moderate Recommendation; Evidence Level: Grade B)

The literature is replete with both prospective and retrospective cohort studies of male sling placement for IPT. However, insufficient follow-up, different definitions of incontinence prior to treatment, variable definitions of “cure” and “improvement” following treatment, and use of a plethora of validated and non-validated outcome measures limits the ability to accurately compare the various male sling options currently available to patients.

Ten prospective¹⁵¹⁻¹⁶⁰ and five retrospective cohort studies¹⁶¹⁻¹⁶⁵ met criteria for inclusion in analysis for this Guideline in determining the cure rate for male sling surgery for the treatment of IPT. The 15 studies included 758 patients, 470 of whom were considered cured by the respective investigator. Definition of “cure” varied from zero pads/day, one pad/day, or a negative one-hour pad test. Overall, 62% of patient achieved cure (range: 34% to 91%); 95% CI: 0.51 to 0.72.

The cohort studies did not include patients with radiation, and some excluded those with severe incontinence, generally considered >500g urine per day leakage, or >5 pads per day. For those studies that included patients with severe leakage, sling failure was generally highest in that sub-group. Complications are not consistently reported, but in general, complication rates are low, with urinary retention typically resolving within one week, and pelvic and perineal pain and paresthesia resolving within 12 weeks. Erosion of the male sling is exceedingly rare.¹⁶⁶ If

this happens, however, removal of the sling is necessary. Prior male sling does not typically interfere with subsequent sling revision or placement of an artificial sphincter in the setting of an unsatisfactory continence outcome.¹⁶⁷

21. Clinicians should not routinely implant male slings in patients with severe stress incontinence. (Moderate Recommendation; Evidence Level: Grade C)

Men suffering with severe SUI electing treatment should not have a male sling and should consider an AUS. Male slings have been shown to have poor efficacy in comparison to an AUS in this subset of patients.^{168, 169} Clinicians might consider a sling in patients who have not undergone radiation, who have minimal incontinence at night, bothersome isolated climacturia, or who would be unable to use the AUS given poor hand function or cognitive abilities. If a sling procedure is done, it would be imperative to counsel the patient regarding appropriate expectations.

22. Clinicians may offer adjustable balloon devices to non-irradiated patients with mild to moderate stress urinary incontinence after prostate treatment. (Conditional Recommendation; Evidence Level: Grade C)

In 2017, adjustable balloon devices became available in the United States for the treatment of male intrinsic sphincter deficiency after prostatectomy or TURP. There has been a marginal increase in clinical experience in the United States since the initial Guideline publication in 2019. Overall, evidence has been supplemented with longer cohort follow-up and meta-analyses.¹⁷⁰⁻¹⁷⁴

In pooled data, patients with all degrees of incontinence have cure and improvement rates of 55% (95% CI: 47 to 63) and 80% (95% CI: 72 to 87), respectively.¹⁷¹ Nash et al. presented the 4-year follow-up of a pre-market study that demonstrated an overall >50% pad reduction of 77.3% in a non-irradiated cohort with comparable improvements in mildly, moderately, and severely incontinent subjects.¹⁷⁰ Other studies with similar follow-up length have reported equivalent results.^{174, 175} Like slings and AUS, RT negatively affects success and is associated with a higher complication rate.^{173, 176}

The success of an intervention must be weighed against the revision and complication rate. The intraoperative and early complication rates of adjustable balloons tend to be

higher than other anti-incontinence procedures. The most common intraoperative complication is urethral or bladder perforation – 5.3% (3.4% to 8%).¹⁷² The mean all-cause (i.e., erosion, infection, balloon migration or balloon failure) explantation rate is 27% (range: 7% to 55%).¹⁷³

While adjustable balloon devices demonstrate efficacy for incontinence, providers should be aware of the unique intraoperative complications and device management. Serial additions of contrast solution to the balloons in the outpatient clinic will optimize efficacy. Adjustable balloons have an advantage in procedure length, less invasive placement, and elimination of the need for patient manipulation. Device removal is more common than AUS.¹⁷⁷ Efficacy, complication rates, and complication types have been proven to be directly linked to case numbers.¹⁷⁸ Thus, obtaining specialty training from an experienced implanter would be beneficial before device implantation.

23. Clinicians should manage patients with stress urinary incontinence after treatment of benign prostatic hyperplasia the same as patients that have undergone radical prostatectomy. (Moderate Recommendation; Evidence Level: Grade C)

BPH is one of the main causes of lower urinary tract symptoms in men. Around 30% of men over age 65 are diagnosed with BPH.¹⁷⁹ Transurethral removal of prostate tissue (e.g., TURP, laser TURP, holmium laser enucleation of the prostate) or open simple prostatectomies are offered to men in whom behavioral and drug therapy fail to relieve symptoms. The rate of persistent SUI in patients undergoing open laparoscopic or endoscopic surgical management of BPH ranges between 0% to 8.4%.^{179, 180} Evaluation of patients with SUI after surgical therapy for BPH should be similar to those who have undergone RP; however care must be taken to rule out a primary bladder pathology such as OAB. Management of SUI after surgical management of BPH should follow the algorithm as that of a patient who underwent RP for prostate cancer. Patients who fail conservative measures should be offered surgical management. However, it should be noted that literature on surgical outcomes in this patient population is limited. Most studies evaluating results of AUS or male sling either combine BPH patients with RP patients or exclude them. There are a few studies that have demonstrated that AUS or male sling are safe and efficacious. A

Cochrane review only identified one RCT evaluating surgical management of SUI after BPH surgery.¹⁷⁹ This study compared the efficacy of AUS implantation versus injectable therapy. Men undergoing AUS placement were more likely to be dry with an odds ratio (OR) of 5.67. Another study in which 56 patients were undergoing AUS placement after TURP found that continence was significantly improved in 90% of patients with a satisfaction rate of 87%,¹⁸¹ and 14 patients required surgical revisions of their AUS. A study looking at 18 men undergoing transobturator male sling after TURP¹⁸² found that 47% of men were cured and 60% were cured or improved using a cure definition of 0 to 5g in the 24-hour pad test. In another study evaluating the use of the quadripolar male sling, four of eight patients were continent and two were improved at one year follow-up.¹⁸³

24. In patients with stress urinary incontinence after primary, adjuvant, or salvage radiotherapy who are seeking surgical management, clinicians should offer artificial urinary sphincter over male slings or adjustable balloons. (Moderate Recommendation; Evidence Level: Grade C)

Over the last decade there has been an increase in the use of multimodal therapy for prostate cancer including adjuvant RT.¹⁸⁴ Radiation causes small vessel obliteration and endarteritis, resulting in ischemic tissue changes such as fibrosis and necrosis, ultimately affecting continence and outcomes following AUS or sling placement.^{185, 186} Patients with IPT following primary, adjuvant or salvage RT should be offered the same conservative management as a patient with post-prostatectomy SUI. Patients who fail conservative measures should be offered surgical management, preferably placement of AUS. Radiated patients undergoing AUS placement should be counseled on potentially compromised functional outcomes and an increased risk of complications. Overall, 66% of radiated patients will demonstrate significant improvement in their continence after AUS placement. However, when compared to the non-radiated patients, continence in the radiated patient after AUS placement may be compromised. Previous studies evaluating AUS placement in radiated versus non-radiated patients have shown mixed results, with some demonstrating equivalent and some worse outcomes in the radiated group.^{118, 137, 187, 188} However, a more contemporary cohort study comparing continence outcomes in radiated versus non-radiated patients showed that 89% of non-radiated

patients were continent compared to 56% in the radiated group.¹⁴¹

Radiated patients may also be at increased risk of complications after AUS placement. A 2015 meta-analysis demonstrated that AUS revision was higher in radiated patients than in non-radiated patients with a random effects risk ratio of 1.56 and a risk difference of 16%.¹⁸⁹ Most of the revisions in the radiated group were secondary to erosion, whereas they were secondary to urethral atrophy in the non-radiated group. A study evaluated whether temporal improvements in RT technique impacted AUS outcomes.¹⁹⁰ Patients undergoing RT after 2007 had equivalent outcomes to those undergoing RT before 2006. As a result, the Panel recommends that patients with RT for prostate cancer, whether as monotherapy or in combination with surgery, be counseled equivalently regarding the outcomes, risks, and complications associated with anti-incontinence surgery.

Since the original Guideline publication, additional reports have become available regarding sling efficacy and outcomes in the radiated population. References to the bone anchor sling are now historical.^{153, 164, 165} Literature on transobturator fixed slings has continued to expand.^{191, 192} Simultaneously, the U.S. field of available and pending devices in the adjustable sub-group continues to evolve with tension adjustment and injectable pillow based products, respectively.¹⁹³ In general, radiation has been correlated with decreased efficacy and an accelerated failure rate in all sling types compared to non-radiated cohorts.^{88, 89, 194-198} However, there is some evidence that radiated patients with a “normal” cystoscopic appearance and good pelvic floor function may benefit from male slings.¹⁹⁹ In a small two center cohort study, Li Marzi et al. demonstrated fixed sling results equivalent to non-radiated when the radiated patients had a positive repositioning test, normal compliance, normal capacity, and no BNC.¹⁹⁹

As stated in Statement 22, RT negatively affects the efficacy and complication rate with adjustable balloons. A recent meta-analysis comparing the adjustable balloons and the injectable pillow sling supports the above viewpoint that while sling usage may be a potential in some radiated patients, adjustable balloons are significantly less effective.¹⁷¹ The majority of literature is

in accord with the opinion that usage is optimal in the non-radiated patient.¹⁷³

25. In patients with incontinence after prostate treatment, clinicians should counsel patients that efficacy is low and cure is rare with urethral bulking agents. (Strong Recommendation; Evidence Level: Grade B)

There are currently no FDA-approved available agents for the treatment of male incontinence, and while the use of bulking agents to treat SUI is considered off-label, they remain the most commonly used procedure.²⁰⁰ This is likely because urethral bulking agents are the least invasive technique available; however they are also the least effective surgical technique in the treatment of male SUI. The utilization of materials to improve urethral coaptation evolved from initial application in females for intrinsic sphincter deficiency.²⁰¹

Injectable therapy is a consideration in patients who are unable to tolerate or refuse more invasive surgical therapy. In male patients, the best success rates have been described in patients with a high Valsalva leak point pressure, unscarred vesicourethral anastomosis, and no RT history.^{27, 202, 203} Data on the efficacy of injectable agents, including collagen, carbon coated zirconium beads, and silicone implants, in male patients are generally limited by the number of reports, patient cohort size, and length of follow-up.

In the largest published study of the utilization of collagen for male SUI, improvement was reported in approximately 50% of patients with a mean duration of 6 months whereas complete continence was achieved in 17% with a mean duration of 9 months. Of note, 1.5% of patients reported an increase in incontinence following collagen injections.²⁰⁴

Success with the injection of carbon coated beads in male patients is characterized by transient partial improvement and risk of retention. Efficacy of carbon beads has been studied in the treatment of mild to moderate IPT. In a study of eight patients who had SUI after RP, only three patients reported subjective transient improvement and five patients opted for a more invasive surgical option after injection of pyrolytic carbon microspheres.²⁰⁵ One patient reported worsening of his incontinence and another had acute urinary retention requiring an indwelling catheter for four days.

Injectable polydimethylsiloxane is a large molecule with a mean diameter of 140 μ m that becomes encapsulated in fibrin and collagen, thereby minimizing the risk of migration. However, due to its size and associated viscosity, special equipment is required for particle delivery.²⁷ Reported efficacy in post prostatectomy patients ranges widely from 10% to 80%. The associated complications rates are variable: urinary retention (6% to 18%), urinary frequency (0% to 72%), dysuria (0% to 100%), and rarely urinary tract infection (0% to 6%).^{206, 207}

26. Clinicians should consider other potential treatments for incontinence after prostate treatment as investigational, and patients should be counseled accordingly. (Expert Opinion)

Outside of PFMT, AUS and perineal sling, no other IPT interventions have vigorous data to support sustained efficacy. There have been some promising results reported in small case series for interventions such as extracorporeal magnetic intervention²⁰⁸ and penile vibratory stimulation.²⁰⁹ More data in larger cohorts are needed to better understand these treatment's durability in treating IPT; as such patients should be counseled accordingly regarding the lack of outcome data. Stem and regenerative cell injections also offer a potential new form of intervention for treating IPT. However, patients should be counseled that this is considered investigational. Patients wishing to pursue this modality should be referred to clinical research trials where safety and outcomes are monitored.

COMPLICATIONS AFTER SURGERY

27. Clinicians may counsel patients regarding risk factors for artificial urinary sphincter erosion. (Conditional Recommendation; Evidence Level: C)

Radiation

The etiology of the tissue compromise related effects of radiation are reviewed in Statement 24. Theoretically, these changes result in poor vascular supply, making the urethra more vulnerable to long-term cuff compression. The evidence strength for the impact of radiation therapy on erosion rate and device failure is the strongest of all studied risk factors.²¹⁰ The sentinel paper from Raj et al. reported the relative risk for erosion of 2.97 (95% CI: 1.69 to 5.20) in radiated patients.²¹¹ More recently, a multi-institutional group led by Kaufman et al. demonstrated that among patients with idiopathic erosion, radiated

subjects had significantly shorter erosion-free device survival in comparison to non-radiated (1.00 year [95% CI: 0.36 to 3.00] versus 3.15 years [95% CI: 1.95 to 5.80]).²¹² Similarly, Huang et al. reported a shorter time to all-cause device failure in radiated AUS patients (e.g., erosion, infection, mechanical failure), with a median of 1.4 years versus 3.5 years in non-irradiated control and a higher 5-year cumulative incidence of erosion/infection (25% versus 6%).²¹³

Prior Urethral Surgery

In addition to radiation, urethral compromise due to surgical intervention, including urethroplasty, multiple treatments for BNC or stricture, urethral stent placement, and prior AUS erosion is a central component of the high-risk urethra.²¹⁴ In a prospective analysis by Sayedahmed et al., patients with prior urethroplasty were shown to have a risk of erosion (OR: 4.182) and decreased erosion-free survival (40.5 versus 51.1 months).²¹⁵ Other investigators have also identified the post-urethroplasty erosion rate to be elevated, with HRs ranging from 2.12 to 8.14.²¹⁶⁻²¹⁸ Currently, there is no evidence whether non-transecting urethroplasty is associated with a decreased erosion risk. Brant et al. showed that prior urethral stenting was an independent risk factor for device explantation (OR: 5.75; 95% CI: 1.23 to 28.8).²¹⁴

Cuff Size

The introduction of the 3.5cm cuff combined with the structural differences compared to the larger cuffs resulted in evaluation regarding increased risk of erosion. Simhan et al. initially reported an increased erosion rate in radiated patients with 3.5cm cuffs versus non-radiated (21% radiated versus 4% non-radiated).²¹⁹ In a longer-term evaluation of the same cohort, a history of radiation therapy, prior AUS cuff erosion, prior urethroplasty, and history of inflatable penile prosthesis (IPP) placement were significantly associated with erosion instead of cuff size.²¹⁸ Conversely, a large multicenter European study by Queissert et al. reported higher erosion rates for smaller cuff sizes and radiated patients.²²⁰

Technique (Transverse Scrotal, Transcorporal)

The transverse scrotal (penoscrotal) technique first popularized in 2003 has been associated with more distal cuff placement, lower dry rates, smaller mean cuff sizes and higher erosion rates.^{1, 220, 221} Thus, practice has deviated from this technique except for specific situations. Transcorporal cuff (TC) placement is utilized as a strategy

for supplementing the urethra with tunica albuginea with the goal of decreasing erosion.²²² However, in recent reports, the transcorporal approach has not been protective against future erosion.²²³ Other groups focused on erosion risk factors in the high-risk urethra have not identified the TC approach as an independent risk factor for erosion.²¹⁶ From a technical standpoint, options may be limited by the atrophic urethra requiring additional soft tissue for appropriate cuff sizing.

28. Clinicians should counsel patients that the artificial urinary sphincter will likely lose effectiveness over time, and reoperations are common. (Strong Recommendation; Evidence Level: Grade B)

AUS is an implant used for the treatment of stress-predominant IPT. The current version consists of a hydraulic system composed of three separate parts: a urethral cuff of varying sizes, a pressure regulating balloon reservoir with three available pressure profiles, and a control pump. The device will fail if any of the three parts, the tubing, or connections suffer a micro-perforation with loss of fluid. The rate of device failure increases with time, with failure rates of approximately 24% at 5 years²²⁴ and 50% at 10 years.¹⁴⁵

A malfunctioning AUS does not necessarily need to be replaced, but if the patient is healthy and requests a replacement, the AUS can be explanted and a new one replaced at the same operative setting. The durability and efficacy of a secondary re-implant in this setting is the same as that of a primary AUS.²²⁴

Device infection and cuff erosion are also causes of reoperation and should be discussed in detail with the patient prior to implantation of the AUS. Device infection is quite uncommon, with rates in long-term series ranging from less than 1% up to 5%.^{145, 225} It is a dramatic presentation with pain at the site of the AUS; fever; scrotal warmth or erythema; or skin changes and necessitates an urgent explantation of the device. An AUS should not be replaced in the setting of infection for at least three months to allow the infection to clear and inflammation to subside. Cuff erosion can be due to unrecognized urethral injury at the time of initial surgery or more likely due to subsequent instrumentation of the urethra including catheterization. Rate of erosion is difficult to obtain due to varying patient populations and techniques but typically range from 1% to 10% on long-term follow-up.^{145, 225} A cuff erosion can present insidiously but generally presents

with hematuria, dysuria, or difficulty emptying the bladder and is diagnosed with a cystoscopic demonstration of the AUS cuff within the urethra.^{226, 227} Management of cuff erosion is via AUS explant with the urethral catheter left in place for a few weeks to allow the urethral defect to heal. Similar to an infection, the AUS should not be reimplanted until at least three months and preferably at a different location along the urethra. In this setting, a transcorporal approach may be used.

Finally, an AUS might need to be replaced over time due to persistent or recurrent incontinence generally due to urethral atrophy, improper cuff sizing, or partial fluid loss.

As previously stated, secondary AUS placements generally have similar outcomes to primary AUS placements;^{224, 225, 228} however, patient satisfaction is driven by the degree of continence after AUS and not by the number of reoperations.^{143, 229}

29. In patients with persistent or recurrent urinary incontinence after artificial urinary sphincter or sling, clinicians should again perform history, physical examination, and/or other investigations to determine the cause of incontinence. (Clinical Principle)

In the patient with persistent urinary incontinence after AUS placement, a history and physical examination is necessary. In the case of the patient inadvertently deactivating the device or inadequately cycling the device, re-education must be performed to ensure that the device is being utilized properly. In the event that an acute fluid loss is suspected, the volume in the pressure regulating balloon can be assessed using computerized tomography or ultrasound.²³⁰ Cuff coaptation may be evaluated by cycling the device during cystoscopic visualization. Although rare, poor coaptation in the absence of fluid loss in the early post-operative phase is related to improper cuff sizing or incomplete engagement of the cuff tab. Either situation can only be addressed by operative revision.

Recurrent incontinence after years of normal function suggests either development of a new leak due to wear or urethral atrophy (with or without erosion). A leak can be confirmed by decreased volume in the pressure regulating balloon, which can be assessed by using ultrasound or computerized tomography.²³⁰ The mainstay for evaluation of atrophy and erosion is cystoscopy.

In a patient with a normally functioning AUS, as determined by physical examination and imaging, leakage due to elevated storage pressures or detrusor over-activity should be suspected. UDS may be performed to evaluate filling pressures, capacity, presence of uninhibited detrusor contractions, and effective voiding. As a technical point, the cuff needs to be temporarily deflated and deactivated to allow for safe and atraumatic urodynamic sensor placement. If there are concerns regarding cuff damage, cystoscopy must be performed immediately to evaluate. In all cases of detrusor dysfunction, the underlying abnormalities must be addressed rather than performing any adjustments to the AUS with the exception of deflating and deactivating in the patient experiencing retention.

30. In patients with persistent or recurrent stress urinary incontinence after sling, clinicians should recommend an artificial urinary sphincter. (Moderate Recommendation; Evidence Level: Grade C)

Failure of a male sling can be due to infection or erosion, or more likely, due to patient dissatisfaction with continence recovery. Rates of infection or erosion after male slings are thought to be very low with almost no long-term series of outcomes reporting these events. However, if a male sling is thought to be infected or documented to be eroded on cystoscopy, the management is similar to management of an infected or eroded AUS. Specifically, in this setting as much of the sling should be explanted as soon as possible with a catheter left in place in the setting of an erosion.

In patients who are not satisfied with the results of a sling due to inadequate continence recovery, a subsequent AUS is the most efficacious option. While a secondary sling can be performed with cure rate of about 45% and satisfaction rates of approximately 70% in highly experienced centers,^{152, 231, 232} most authors recommend an AUS in this setting. A retrospective cohort study of 61 men looked at continence outcomes between salvage AUS and secondary transobturator slings.²³² Twenty-nine men underwent a repeat sling and 32 underwent an AUS following sling. Repeat sling patients had a failure rate of 55% compared to 6% after AUS. Multiple authors have shown that AUS after sling^{233, 234} have similar outcomes to primary AUS, and the Panel recommends an AUS following sling failure.

31. In patients with persistent or recurrent stress urinary incontinence after artificial urinary sphincter, clinicians should discuss artificial urinary sphincter revision with the patient. (Strong Recommendation; Evidence Level: Grade B)

Patients with persistent or recurrent incontinence or those dissatisfied with their continence recovery after AUS placement should undergo evaluation. Inadequate recovery of continence after AUS placement can be due to a host of factors, including suboptimal cuff sizing at the time of original operation or inadequate pressure regulating balloon gradient.

The original operative report should be evaluated to note surgical approach, size of urethral cuff, and location of pressure regulating balloon. In patients with a possible distally located cuff, or those with a larger cuff, proximal relocation or downsizing of the cuff are both reasonable options and will likely lead to better continence.

Tandem cuff placement is the addition of a cuff to the original cuff and has also been shown to be effective as a salvage procedure for patients with persistent incontinence. Specific additional risks of tandem cuff placement should be discussed with the patient prior to proceeding. Such risks include injury to the urethra during dissection, which would lead to aborting the case and the higher risk of subsequent erosion.

Some authorities have advocated moving the pressure regulating balloon to a different location or replacing it with a higher-pressure balloon.^{235, 236} Others have used a transcervical approach to improve urethral coaptation in patients with small urethral caliber, especially in the setting of prior RT and/or erosion;²³⁷ however there is limited evidence to support either of these approaches.

Any of the above maneuvers can be combined with replacement of an AUS at the time of device failure. It is important to note that, in general efficacy and durability after secondary AUS placement appear to be similar to those after primary AUS placement, except in the setting of erosion.^{224, 225, 228}

32. In patients presenting with infection or erosion of an artificial urinary sphincter or sling, clinicians should perform explantation and reimplantation should be delayed. (Clinical Principle)

Similar to other synthetic devices, explantation is indicated in cases of AUS or male sling device infection. Timing of removal is usually influenced by severity of the infection and acuity of the clinical situation as indicated by the associated signs and symptoms (e.g., purulent drainage, erythema, tenderness, fever, chills). In general, explantation should be performed as soon as possible. In the case of the AUS, the most conservative course of action is removal of all components, regardless of whether the infection and any associated reaction are limited to a single component. Even in the absence of purulent fluid and erythema, a wash-out procedure combined with immediate device replacement has not been consistently proven to be reliable or effective.²³⁸ As discussed previously, an infected male sling should be removed as completely as feasible without damaging any adjacent structures.

Often times an infection is secondary to a pre-existing erosion. AUS isolated cuff infections are rare without an associated erosion. Like infection, erosion requires device explantation. The urethral defect will usually heal by leaving a urethral catheter in place for three weeks. Some authors, however, recommend a urethral repair in cases of larger urethral defects due to decreased rates of stricture.²³⁹

For patients seeking a replacement device (AUS or male sling) after infection and/or erosion, a waiting period of three to six months is recommended. In the AUS patient, it may be necessary to proceed with transcervical placement of the cuff.^{222, 240} This approach would be recommended in the radiated patient with the prior erosion with thinned spongiosal tissue who has insufficient tissue to obtain a satisfactory fitting cuff. Xenograft tissue buttressed to supplement the urethra (theoretically decreasing risk of erosion) has been associated with significant complications and has not been advantageous.^{241, 242}

33. After explanting an eroded device, clinicians may manage artificial urinary sphincter urethral cuff erosion intra-operatively with urethral catheter alone, in situ urethroplasty, or anastomotic urethroplasty. (Expert Opinion)

AUS cuff erosion is a devastating complication that can lead to urine extravasation, infection, abscess formation and sepsis, and may result in long-term urethral fistula, urethral diverticula, or urethral stricture after AUS explant. The degree of urethral loss with erosion can be highly variable, ranging from a small <5mm hole in the urethra, to complete circumferential urethral loss under the 2cm cuff. During AUS explant, the goal of erosion management is to maximize the chances of urethral healing without developing a fistula or stricture. The decision on how to best manage the erosion takes into consideration the size of the urethral defect, quality of local tissues (there are heterogeneous degrees of inflammation, induration, and fibrosis), and surgeon preference/experience.

A retrospective study analyzing outcomes of three different intraoperative AUS erosion management techniques (i.e., urethral catheter only, abbreviated urethroplasty [AU], or primary urethral anastomosis [PA]) found that management with PA was more common in patients with severe erosion (erosion>50% of urethral circumference) than with urethral catheter or AU groups (100% versus 37%; $p<0.001$; 100% versus 38%; $p<0.001$). In addition, cuff erosions treated with PA were more likely to be severely eroded than cuff erosions treated with urethral catheter or AU (100% versus 35%; $p<0.001$; 100% versus 42%; $p<0.001$).²⁴³ Additionally, severe erosions treated with urethral catheters were more likely to develop strictures than mild erosions (38% versus 5%; $p: 0.009$).

Similarly, Rozanski et al. demonstrated a dramatically lower rate of stricture formation (38% versus 85%) and a decrease in the delay of AUS replacement (9 months versus 17 months) in patients receiving an abbreviated in situ urethroplasty with urethral catheter compared to those managed with urethral catheter only.²³⁹

In another study, patients treated with in situ urethroplasty for urethral erosion who went on to revision AUS were more likely to eventually require urinary diversion if the erosion involved >33% of the urethral circumference at the initial erosion event.²⁴⁴ Patients with erosions <33% of the urethral circumference had lower rates of lower urinary tract complications (i.e., urethral fistula, diverticula, urethral stricture) compared to patients with erosions >33% urethral circumference (17% versus 68% despite both have in situ urethroplasty management of the erosion).²⁴⁴

SPECIAL SITUATIONS

34. Clinicians should discuss urinary diversion with patients who are unable to obtain long-term quality of life due to incontinence after prostate treatment. (*Expert Opinion*)

In patients who are unable to obtain a satisfactory QoL long-term with an AUS due to multiple device failures, intractable BNC, or severe detrusor instability, urinary diversion with or without cystectomy may be an option. If bladder preservation is feasible, conversion to a Mitrofanoff (e.g., Appendix, Monti), incontinent ileovesicostomy, or suprapubic tube with bladder neck closure may confer an improved QoL. In the event of the “hostile” bladder, cystectomy in combination with either an ileal conduit or continent catheterizable pouch would best manage incontinence while protecting the upper tracts.

35. In patients with bothersome incontinence during sexual activity, clinicians should offer treatment. (*Moderate Recommendation; Evidence Level: Grade C*)

As with post-prostatectomy SUI, for those with sexual arousal incontinence or climacturia, conservative management should be the initial treatment. The complaint may resolve in two-thirds of patients over time.⁵⁴ For those with persistent leakage, behavioral management includes dehydration and emptying the bladder prior to sex, use of condoms to catch the urine, achieving orgasm while supine, and PFME, which has demonstrated improvement in one small randomized trial.⁶⁰

Anecdotal success has been reported with the tricyclic antidepressant imipramine, but this medication is generally contraindicated in men over the age of 65 years due to the risk of somnolence, falling down, and changes in cognition.²⁴⁵

The use of a penile variable tension loop (a soft silicone tube placed around the penis and adjusted to provide pressure on the urethra to physically prevent leaking during sex) has been used with success, decreasing the degree of orgasm-associated leakage in those with mild, moderate, and even severe self-reported leakage. Decreasing distress has been reported in both patients and partners, from 14% to 2% and 61% to 11%, respectively.²⁴⁶

Both the AUS and the transobturator male sling, when implanted for daytime SUI, are associated with high rates of improvement in climacturia, similar to the rates of improvement in SUI.^{247, 248} In patients who also have erectile dysfunction and are undergoing an IPP, a small mesh or autologous graft anchored to the medial aspects of the bilateral corporotomies to improve incontinence during sexual activity, with 93% noting improvement post-operatively.²⁴⁹ The mechanism of action is one where the mesh compresses the bulbar urethra as the IPP cylinders expand with inflation.

36. In patients with stress urinary incontinence following urethral reconstructive surgery, clinicians may offer artificial urinary sphincter and counsel that complications rates are higher. (*Conditional Recommendation; Evidence Level: Grade C*)

Urethral strictures of the anterior urethra and urethral stenosis of the posterior urethra can arise after RP, RT, or treatment for IPT.²⁵⁰ Anterior urethral strictures may be synchronous with prostate-related conditions and persist after treatment, occur *de novo* after therapy for prostate-related conditions or arise after an AUS erosion. Posterior urethral stenosis typically arises after treatment for prostate-related conditions. Urethral reconstructive surgery is often used to treat narrowing in the urethra. Often IPT exists prior to urethroplasty or is caused by urethral reconstruction in rare cases. AUS is the preferred surgical treatment for IPT after urethral reconstruction. Depending on the technique employed (urethra transecting or not) the blood supply to the urethra may be diminished and potentially decrease the life span of an AUS. Transcorporal placement of the AUS might be beneficial in some cases due to concerns about alterations in urethral blood supply. AUS can be successfully replaced after erosion-related urethral strictures and subsequent reconstruction.²⁵¹ Given post-surgical changes related to most types of urethral reconstruction in the posterior and anterior urethra, male slings will not be effective.

37. In patients with incontinence after prostate treatment and erectile dysfunction (ED), clinicians may offer a concomitant or staged procedure. (*Conditional Recommendation; Evidence Level: Grade C*)

In patients with both IPT and post-prostatectomy ED, concomitant surgery to treat both conditions should be

considered. Though initial investigations showed concern for infection during concomitant surgery, various studies have demonstrated that concomitant surgery is safe and may actually provide significant benefits.^{252, 253} In a report of 55 patients undergoing combined penile prosthesis and AUS surgical procedures, combined procedures had a significantly longer operative time;²⁵⁴ however, the rate of device infection, erosion or malfunction was not increased in combined compared to staged procedures. Another study described similar continence, sexual function, and overall satisfaction in patients undergoing staged versus combined procedures.²⁵⁵ Despite these positive results of concomitant surgery most recent study using the SPARCS (New York State Department of Health Statewide Planning and Research Cooperative) database found that men undergoing combination of penile prosthesis and AUS placement had a higher rate of reoperation compared to men undergoing penile prosthesis alone.²⁵⁶ Even though combination surgery is feasible, men considering surgical management of both ED and SUI should be counseled of the possible increase risk of complications.

38. In patients with symptomatic vesicourethral anastomotic stenosis (VUAS) or bladder neck contracture, clinicians should treat the patient prior to surgery for incontinence after prostate treatment. (Clinical Principle)

Patients who are diagnosed with a symptomatic VUAS or BNC should have treatment of their obstruction prior to surgical correction of their incontinence. Following treatment of VUAS, an interval cystoscopy should be performed at least four to six weeks later to document improvement and stabilization, after which IPT treatment can be considered. Although a VUAS or BNC will not necessarily cause SUI, treatment of them may worsen SUI. This is important because a patient may be considered for a sling procedure if he had “mild” incontinence, but he would likely need an AUS if it worsens after treatment. It is also generally felt that patients with a VUAS or BNC have decreased success rates when undergoing male slings; therefore, an AUS would generally be considered a better option in this group.¹⁶⁸

Treatment of a VUAS or BNC after a sling or AUS could be difficult or might place the patient at a higher risk of complications such as worsening of urinary incontinence, erosion of the AUS cuff, or possible infection. Endoscopic

treatment of VUAS/BNC after AUS has been described using a semi-rigid ureteroscope and holmium laser although this is still not the optimal approach.²⁵⁷

FUTURE DIRECTIONS

In the future, refinements to therapies that create IPT will occur, decreasing incidence. The Panel expects continued enhancements in diagnostics and treatment options that will continue to improve patient continence and decrease the prevalence of IPT. Since most papers are single center experiences, the Panel expects and hopes to have increased multicenter research collaboration. Clinical trials of lifestyle interventions, medications, and surgeries will be needed to estimate therapeutic benefit while comparative effectiveness research can help determine which therapy to use and when. Patient reported outcome measures, which are very important in the treatment of QoL surgery have also become more prevalent; as such, the Panel expects these to also improve in use and quality, allowing clinicians to fully address patient concerns.

Refining which patient populations with SUI and BNC/VUAS will benefit from synchronous BNC/VUAS treatment and AUS placement rather than staged procedures will improve the QoL of many patients.

Newer treatments will encompass not only improvements in surgical products such as AUS and male slings, but will also include continued research into muscle injections, stem cells, and newer treatments for urgency and urge incontinence.

Developments regarding surgical products will likely include improvements to the current AUS, possibly improving the patient’s ability to use the pump. It may also include a more automated system controlled from an external device with no manual dexterity needed. With newer technologies, the Panel hopes to see automatic adjustments in cuff pressures or fluid volumes that would allow increased pressures improving continence with any increase in abdominal pressure. Dynamic pressuring could lead to less leakage and less wear on the urethra.

Male slings have continued to evolve from bone anchored slings to the current products on the market, including some that are adjustable. As clinicians learn more about etiology, continued development and improvements will increase efficacy of newer products.

The ATOMS® adjustable transobturator sling is currently approved for use in Europe and Canada; however, it is currently under review by the FDA. New evidence demonstrates that the ATOMS® adjustable sling is safe and effective for men with mild to severe SUI. However, patients with prior RT and prior surgery for urethral stricture had significantly worse continence rates, complication rates, and satisfaction rates compared to those who did not have these risk factors.^{2, 198}

Some advances in the treatment of male SUI are expected to parallel those with female SUI. Regenerative medicine may shape future treatments attempting to restore normal function with either autologous muscle-derived cells or multipotent mesenchymal stem cells injected into the sphincter. While cell-based therapies have yet to produce long-term clinical improvement, hope exists that cellular regenerative therapies such as stem cells or low-intensity shockwave will lead to effective non-surgical therapies.

ABBREVIATIONS

| | | | |
|--------|---|------|---|
| 95% CI | 95% confidence interval | TC | Transcorporal cuff |
| AU | Abbreviated urethroplasty | TURP | Transurethral resection of the prostate |
| AUA | American Urological Association | ULR | Update literature review |
| AUAER | American Urological Association Education and Research, Inc. | UDS | Urodynamic testing |
| AUS | Artificial urinary sphincter | VUAS | Vesicourethral anastomotic stenosis |
| BMI | Body mass index | | |
| BNC | Bladder neck contracture | | |
| BOD | Board of directors | | |
| BPH | Benign prostatic hyperplasia | | |
| ED | Erectile dysfunction | | |
| FDA | U.S. Food and Drug Administration | | |
| GURS | Society of Genitourinary Reconstructive Surgeons | | |
| HIFU | High intensity focused ultrasound | | |
| IPP | Inflatable penile prosthesis | | |
| IPT | Incontinence after prostate treatment | | |
| MRI | Magnetic resonance imaging | | |
| OAB | Overactive bladder | | |
| OR | Odds ratio | | |
| PA | Primary urethral anastomosis | | |
| PFME | Pelvic floor muscle exercise | | |
| PFMT | Pelvic floor muscle training | | |
| PGC | Practice guidelines committee | | |
| PVR | Post-void residual | | |
| QoL | Quality of life | | |
| RCT | Randomized controlled trial | | |
| RP | Radical prostatectomy | | |
| RT | Radiation therapy | | |
| SQC | Science and Quality Council | | |
| SUFU | Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction | | |
| SUI | Stress urinary incontinence | | |

INCONTINENCE AFTER PROSTATE TREATMENT PANEL, CONSULTANTS, AND STAFF

Panel 2019

Jaspreet S. Sandhu, MD (Chair)
Memorial Sloan Kettering Cancer Center

Kurt McCammon, MD (Vice Chair)
Eastern Virginia Medical School

Benjamin Breyer, MD
University of California San Francisco

Craig Comiter, MD
Stanford University

James A. Eastham, MD
Memorial Sloan Kettering Cancer Center

Christopher Gomez, MD
University of Miami

Daniel Kirages, PT, DPT
University of Southern California

Chris Kittle (Patient Advocate)

Alvaro Lucioni, MD
Virginia Mason

Victor Nitti, MD
University of California, Los Angeles

John T. Stoffel, MD
University of Michigan

O. Lenaine Westney, MD
MD Anderson Cancer Center

Consultant 2019

M. Hassan Murad
Mayo Clinic

Staff 2019

Abid Khan, MHS, MPP
Erin Kirkby, MS
Nenellia K. Bronson, MA
Leila Rahimi, MHS
Brooke Bixler, MH
Shalini Selvarajah, MD, MPH

Amendment Panel 2024

Benjamin Breyer, MD (Chair)
University of California San Francisco

Alex J. Vanni, MD
Lahey Hospital and Medical Center

O. Lenaine Westney, MD
MD Anderson Cancer Center

Consultants 2024

Alexis Marianes, PhD

Staff 2024

Erin Kirkby, MS
Sennett K. Kim
Leila Rahimi, MHS
Lauren J. Pak, MHS, MS

CONFLICT OF INTEREST DISCLOSURES 2019

All panel members completed COI disclosures. Disclosures listed include both topic- and non -topic-related relationships. Panel members not listed below have nothing to disclose.

Consultant/Advisor: **Craig Comiter**, Avails Medical, Neuspera, Better Health; **Kurt McCammon**, Boston Scientific

Employee: **O. Lenaine Westney**, Boston Scientific; **Kurt McCammon**, Urology of Virginia

Health Publishing: **Benjamin Breyer**, World Journal Urology, Sexual Medicine Open Access

Investment Interest: **James Eastham**, 3DBiopsy; **Victor Nitti**, Serenity Pharmaceuticals

Leadership Position: **Kurt McCammon**, IVUMed, **John Stoffel**, Journal of Urology

Scientific Study or Trial: **Craig Comiter**, Zenflow, BE Technologies, **Kurt McCammon**, Allergen, Astellas, Solace, Taris, Cook; **Victor Nitti**, Astellas, Allergen, Medtronic, Amphora; **John T. Stoffel**, Uroplasty, Department of Defense

CONFLICT OF INTEREST DISCLOSURES 2024

All panel members completed COI disclosures. Disclosures listed include both topic- and non -topic-related relationships. Panel members not listed below have nothing to disclose.

Consultant/Advisor: O. Lenaine Westney, Urotronic, Bluewind

Meeting Participant/Lecturer: O. Lenaine Westney, Boston Scientific

Employee: O. Lenaine Westney, Boston Scientific (Family member)

Health Publishing: Benjamin Breyer, World Journal Urology, AUA Update

Other: Alex Vanni, Boston Scientific

Scientific Study or Trial: O. Lenaine Westney, Laborie; Alex Vanni, Ellison Foundation Grant, Robert E. Wise Foundation

PEER REVIEWERS 2019

We are grateful to the persons listed below who contributed to the Guideline by providing comments during the peer review process. Their reviews do not necessarily imply endorsement of the Guideline.

AUA (Board of Directors, Science and Quality Council, Practice Guidelines Committee, Journal of Urology)

Rodney Breau
Pat Fulgham
David Ginsberg
Anne Gormley
Melissa Kaufman
Louis Kavoussi
John Mulhall
Roger E. Schultz
Anthony Smith

External Reviewers (Non-AUA Affiliates)

William Brant
Stuart Boyd
Anne Cameron
Roger Dmochowski
Bradley Gill
Howard Goldman
Alexander Gomelsky
Sender Herschorn

Michael Kennelly
Laura Leddy
Gary Lemack
Mark Litwin
Joshua Meeks
Allen Morey
Robert O'Connor
Drew Peterson
Phillip Pierorazio
Keith Rourke
Eric Rovner
Beth Shelley
Ajay Singla
Jack Zuckerman

Public Commenters (Via public notice on AUA website)

Jordan Dimitrakoff
Kirill Shiranov

PEER REVIEWERS 2024

We are grateful to the persons listed below who contributed to the Guideline by providing comments during the peer review process. Their reviews do not necessarily imply endorsement of the Guideline.

AUA (Board of Directors, Science and Quality Council, Practice Guidelines Committee, Journal of Urology)

Erin Bird, MD
Stephen Boorjian, MD
Sam Chang, MD
David Ginsberg, MD
Damara Lee Kaplan, MD
Kathleen Kobashi, MD
Lara MacLachlan, MD
Stephen Y. Nakada, MD
Matthew Nielsen, MD
Philip Pierorazio, MD
Charles R. Powell II, MD
Angela Smith, MD
Thomas F. Stringer, MD
Arthur Edgar Tarantino, MD

External Reviewers (Non-AUA Affiliates)

Jennifer Anger, MD
Jaime Cavallo, MD
Andrew Cohen, MD
Craig Comiter, MD
James A. Eastham, MD
Sean Elliott, MD
Khushabu Kasabwala, MD
Daniel Kirages, PT
Chris Kittle
Jeff Loh-Doyle, MD



Greg Murphy, MD
Victor Nitti, MD
Alex Rozanski, MD
Jaspreet S. Sandhu, MD
Thomas Smith, MD

Public Commenters (Via public notice on AUA website)

Matan Mekayten, MD
Kirill Shiranov, MD
Matthew Young, MD

DISCLAIMER

This document was written by the Incontinence after Prostate Treatment Panel of the American Urological Association Education and Research, Inc., which was created in 2019 and updated in 2024. The PGC of the AUA selected the Panel Chair. Panel members were selected by the Panel and PGC Chair.

Membership of the panel included specialists with specific expertise on this disorder. The mission of the panel was to develop recommendations that are analysis-based or consensus-based, depending on panel processes and available data, for optimal clinical practices in the early detection of prostate cancer setting.

Funding of the panel was provided by the AUA. Panel members received no remuneration for their work. Each member of the panel provides an ongoing conflict of interest disclosure to the AUA.

While these guidelines do not necessarily establish the standard of care, AUA seeks to recommend and to encourage compliance by practitioners with current best practices related to the condition being treated. As medical knowledge expands and technology advances, the guidelines will change. Today these evidence-based guidelines statements represent not absolute mandates but provisional proposals for treatment under the specific conditions described in each document. For all these reasons, the guidelines do not pre-empt physician judgment in individual cases.

Treating physicians must take into account variations in resources, and patient tolerances, needs, and preferences. Conformance with any clinical guideline does not guarantee a successful outcome. The guideline text may include information or recommendations about certain drug uses ("off label") that are not approved by the

FDA, or about medications or substances not subject to the FDA approval process. AUA urges strict compliance with all government regulations and protocols for prescription and use of these substances. The physician is encouraged to carefully follow all available prescribing information about indications, contraindications, precautions and warnings. These guidelines and best practice statements are not in-tended to provide legal advice about use and misuse of these substances.

Although guidelines are intended to encourage best practices and potentially encompass available technologies with sufficient data as of close of the literature review, they are necessarily time-limited. Guidelines cannot include evaluation of all data on emerging technologies or management, including those that are FDA-approved, which may immediately come to represent accepted clinical practices.

For this reason, the AUA does not regard technologies or management that are too new to be addressed by this guideline as necessarily experimental or investigational.

REFERENCES

1. Henry GD, Graham SM, Cornell RJ et al: A multicenter study on the perineal versus penoscrotal approach for implantation of an artificial urinary sphincter: Cuff size and control of male stress urinary incontinence. *J Urol* 2009; **182**: 2404
2. Giammò A, Ammirati E, Tullio A et al: Implant of atoms® system for the treatment of postoperative male stress urinary incontinence: An Italian multicentric study. *Minerva Urol Nefrol* 2020; **72**: 770
3. Nitti VW, Mourtziros A and Brucker BM: Correlation of patient perception of pad use with objective degree of incontinence measured by pad test in men with post-prostatectomy incontinence: The sufu pad test study. *J Urol* 2014; **192**: 836
4. Suarez OA and McCammon KA: The artificial urinary sphincter in the management of incontinence. *Urology* 2016; **92**: 14
5. Lim B, Kim A, Song M et al: Comparing argus sling and artificial urinary sphincter in patients with moderate post-prostatectomy incontinence. *J Exerc Rehabil* 2014; **10**: 337
6. Methods guide for effectiveness and comparative effectiveness reviews. 2014; **No. 10(14)-EHC063-EF**
7. BA HCaS: The delphi technique: Making sense of consensus. *Practical Assessment, Research & Evaluation* 2007; **1**
8. Barocas DA, Alvarez J, Resnick MJ et al: Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. *JAMA* 2017; **317**: 1126
9. Al Hussein Al Awamih B, Wallis CJD, Penson DF et al: Functional outcomes after localized prostate cancer treatment. *JAMA* 2024; **331**: 302
10. Ávila M, Patel L, López S et al: Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis. *Cancer Treat Rev* 2018; **66**: 23
11. Crouzet S, Chapelon JY, Rouvière O et al: Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: Oncologic outcomes and morbidity in 1002 patients. *Eur Urol* 2014; **65**: 907
12. Khan A, Khan AU, Siref L and Feloney M: Focal cryoablation of the prostate: Primary treatment in 163 patients with localized prostate cancer. *Cureus* 2023; **15**: e37172
13. Chen C, Chen Z, Wang K et al: Comparisons of health-related quality of life among surgery and radiotherapy for localized prostate cancer: A systematic review and meta-analysis. *Oncotarget* 2017; **8**: 99057
14. Jarosek SL, Virnig BA, Chu H and Elliott SP: Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both. *Eur Urol* 2015; **67**: 273
15. Novara G, Ficarra V, D'Elia C et al: Evaluating urinary continence and preoperative predictors of urinary continence after robot assisted laparoscopic radical prostatectomy. *J Urol* 2010; **184**: 1028
16. Kadono Y, Ueno S, Kadomoto S et al: Use of preoperative factors including urodynamic evaluations and nerve-sparing status for predicting urinary continence recovery after robot-assisted radical prostatectomy: Nerve-sparing technique contributes to the reduction of postprostatectomy incontinence. *Neurourol Urodyn* 2016; **35**: 1034
17. Jeong SJ, Kim HJ, Kim JH et al: Urinary continence after radical prostatectomy: Predictive factors of recovery after 1 year of surgery. *Int J Urol* 2012; **19**: 1091
18. Han K-s and Kim C-S: Effect of pubovesical complex reconstruction during robot-assisted laparoscopic prostatectomy on the recovery of urinary continence. *J Laparoendosc Adv Surg Tech A* 2015; **25**: 814
19. Kowalczyk KJ, Huang AC, Hevelone ND et al: Effect of minimizing tension during robotic-assisted laparoscopic radical prostatectomy on urinary function recovery. *World J Urol* 2013; **31**: 515
20. Sacco E, Prayer-Galetti T, Pinto F et al: Urinary incontinence after radical prostatectomy: Incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. *BJU Int* 2006; **97**: 1234
21. Matsushita K, Kent MT, Vickers AJ et al: Preoperative predictive model of recovery of urinary continence after radical prostatectomy. *BJU Int* 2015; **116**: 577
22. Mandel P, Preisser F, Graefen M et al: High chance of late recovery of urinary and erectile function beyond 12 months after radical prostatectomy. *Eur Urol* 2017; **71**: 848
23. Ficarra V, Crestani A, Rossanese M et al: Urethral-fixation technique improves early urinary continence recovery in patients who undergo retropubic radical prostatectomy. *BJU Int* 2017; **119**: 245
24. Choi SK, Park S and Ahn H: Randomized clinical trial of a bladder neck plication stitch during robot-assisted radical prostatectomy. *Asian J Androl* 2015; **17**: 304
25. Jo JK, Hong SK, Byun SS et al: Urinary continence after robot-assisted laparoscopic radical prostatectomy: The impact of intravesical prostatic protrusion. *Yonsei Med J* 2016; **57**: 1145

26. Abdollah F, Sun M, Suardi N et al: Prediction of functional outcomes after nerve-sparing radical prostatectomy: Results of conditional survival analyses. *Eur Urol* 2012; **62**: 42
27. Lee SW, Kang JH, Sung HH et al: Treatment outcomes of transurethral macropastique injection for postprostatectomy incontinence. *Korean J Urol* 2014; **55**: 182
28. Palisaar JR, Roghmann F, Brock M et al: Predictors of short-term recovery of urinary continence after radical prostatectomy. *World J Urol* 2015; **33**: 771
29. Tewari AK, Ali A, Metgud S et al: Functional outcomes following robotic prostatectomy using athermal, traction free risk-stratified grades of nerve sparing. *World J Urol* 2013; **31**: 471
30. Jeong SJ, Yeon JS, Lee JK et al: Development and validation of nomograms to predict the recovery of urinary continence after radical prostatectomy: Comparisons between immediate, early, and late continence. *World J Urol* 2014; **32**: 437
31. Tienza A, Hevia M, Benito A et al: Mri factors to predict urinary incontinence after retropubic/laparoscopic radical prostatectomy. *Int Urol Nephrol* 2015; **47**: 1343
32. Tienza A, Robles JE, Hevia M et al: Prevalence analysis of urinary incontinence after radical prostatectomy and influential preoperative factors in a single institution. *Aging Male* 2017: 1
33. Coughlin GD, Yaxley JW, Chambers SK et al: Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. *Lancet Oncol* 2018; **19**: 1051
34. Ilic D, Evans SM, Allan CA et al: Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. *Cochrane Database Syst Rev* 2017; **9**: CD009625
35. Rocco B, Gregori A, Stener S et al: Posterior reconstruction of the rhabdosphincter allows a rapid recovery of continence after transperitoneal videolaparoscopic radical prostatectomy. *Eur Urol* 2007; **51**: 996
36. Kim IY, Hwang EA, Mmeje C et al: Impact of posterior urethral plate repair on continence following robot-assisted laparoscopic radical prostatectomy. *Yonsei Med J* 2010; **51**: 427
37. Zhao Z, Zhu H, Yu H et al: Comparison of intrafascial and non-intrafascial radical prostatectomy for low risk localized prostate cancer. *Sci Rep* 2017; **7**: 17604
38. Eastham JA, Kattan MW, Rogers E et al: Risk factors for urinary incontinence after radical prostatectomy. *J Urol* 1996; **156**: 1707
39. Kadono Y, Nohara T, Kawaguchi S et al: Comparison of postoperative urinary continence and incontinence types between conventional and retzius-sparing robot-assisted radical prostatectomy. *Neurourol Urodyn* 2023; **42**: 1411
40. Egan J, Marhamati S, Carvalho FLF et al: Retzius-sparing robot-assisted radical prostatectomy leads to durable improvement in urinary function and quality of life versus standard robot-assisted radical prostatectomy without compromise on oncologic efficacy: Single-surgeon series and step-by-step guide. *Eur Urol* 2021; **79**: 839
41. Hatiboglu G, Teber D, Tichy D et al: Predictive factors for immediate continence after radical prostatectomy. *World J Urol* 2016; **34**: 113
42. Ko YH, Coelho RF, Chauhan S et al: Factors affecting return of continence 3 months after robot-assisted radical prostatectomy: Analysis from a large, prospective data by a single surgeon. *J Urol* 2012; **187**: 190
43. Lee DI, Wedmid A, Mendoza P et al: Bladder neck plication stitch: A novel technique during robot-assisted radical prostatectomy to improve recovery of urinary continence. *J Endourol* 2011; **25**: 1873
44. Mottet N, Boyer C, Chartier-Kastler E et al: Artificial urinary sphincter ams 800 for urinary incontinence after radical prostatectomy: The french experience. *Urol Int* 1998; **60 Suppl 2**: 25
45. Sammon J, Kim TK, Trinh QD et al: Anastomosis during robot-assisted radical prostatectomy: Randomized controlled trial comparing barbed and standard monofilament suture. *Urology* 2011; **78**: 572
46. Schlomm T, Heinzer H, Steuber T et al: Full functional-length urethral sphincter preservation during radical prostatectomy. *Eur Urol* 2011; **60**: 320
47. Kaye DR, Hyndman ME, Segal RL et al: Urinary outcomes are significantly affected by nerve sparing quality during radical prostatectomy. *Urology* 2013; **82**: 1348
48. Burkhard FC, Kessler TM, Fleischmann A et al: Nerve sparing open radical retropubic prostatectomy--does it have an impact on urinary continence? *J Urol* 2006; **176**: 189
49. Clavell-Hernandez J, Martin C and Wang R: Orgasmic dysfunction following radical prostatectomy: Review of current literature. *Sex Med Rev* 2017;
50. Röscher P, Sathiram R, Milios JE and van Wyk JM: Mapping the prevalence and use of questionnaires to detect the neglected sexual side effects after prostate cancer treatment: A scoping review. *Syst Rev* 2022; **11**: 2
51. O'Neil BB, Presson A, Gannon J et al: Climacturia after definitive treatment of prostate cancer. *J Urol* 2014; **191**: 159
52. Choi JM, Nelson CJ, Stasi J and Mulhall JP: Orgasm associated incontinence (climacturia) following radical pelvic surgery: Rates of occurrence and predictors. *J Urol* 2007; **177**: 2223

53. Capogrosso P, Ventimiglia E, Serino A et al: Orgasmic dysfunction after robot-assisted versus open radical prostatectomy. *Eur Urol* 2016; **70**: 223
54. Mitchell SA, Jain RK, Laze J and Lepor H: Post-prostatectomy incontinence during sexual activity: A single center prevalence study. *J Urol* 2011; **186**: 982
55. Liss MA, Osann K, Canvasser N et al: Continence definition after radical prostatectomy using urinary quality of life: Evaluation of patient reported validated questionnaires. *J Urol* 2010; **183**: 1464
56. Manassero F, Traversi C, Ales V et al: Contribution of early intensive prolonged pelvic floor exercises on urinary continence recovery after bladder neck-sparing radical prostatectomy: Results of a prospective controlled randomized trial. *Neurourol Urodyn* 2007; **26**: 985
57. Patel MI, Yao J, Hirschhorn AD and Mungovan SF: Preoperative pelvic floor physiotherapy improves continence after radical retropubic prostatectomy. *Int J Urol* 2013; **20**: 986
58. Bales GT, Gerber GS, Minor TX et al: Effect of preoperative biofeedback/pelvic floor training on continence in men undergoing radical prostatectomy. *Urology* 2000; **56**: 627
59. Centemero A, Rigatti L, Giraudo D et al: Preoperative pelvic floor muscle exercise for early continence after radical prostatectomy: A randomised controlled study. *Eur Urol* 2010; **57**: 1039
60. Geraerts I, Van Poppel H, Devoogdt N et al: Pelvic floor muscle training for erectile dysfunction and climacturia 1 year after nerve sparing radical prostatectomy: A randomized controlled trial. *Int J Impot Res* 2016; **28**: 9
61. Parekh AR, Feng MI, Kirages D et al: The role of pelvic floor exercises on post-prostatectomy incontinence. *J Urol* 2003; **170**: 130
62. Burgio KL, Goode PS, Urban DA et al: Preoperative biofeedback assisted behavioral training to decrease post-prostatectomy incontinence: A randomized, controlled trial. *J Urol* 2006; **175**: 196
63. Tienforti D, Sacco E, Marangi F et al: Efficacy of an assisted low-intensity programme of perioperative pelvic floor muscle training in improving the recovery of continence after radical prostatectomy: A randomized controlled trial. *BJU Int* 2012; **110**: 1004
64. Mock S, Leapman M, Stock RG et al: Risk of urinary incontinence following post-brachytherapy transurethral resection of the prostate and correlation with clinical and treatment parameters. *J Urol* 2013; **190**: 1805
65. Hu K and Wallner K: Urinary incontinence in patients who have a turp/tuip following prostate brachytherapy. *Int J Radiat Oncol Biol Phys* 1998; **40**: 783
66. Polland A, Vertosick EA, Sjoberg DD et al: Preoperative symptoms predict continence after post-radiation transurethral resection of prostate. *Can J Urol* 2017; **24**: 8903
67. Lerner SE, Blute ML and Zincke H: Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. *J Urol* 1995; **154**: 1103
68. Stephenson AJ, Scardino PT, Bianco FJ, Jr. et al: Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. *J Urol* 2004; **172**: 2239
69. Gotto GT, Yunis LH, Vora K et al: Impact of prior prostate radiation on complications after radical prostatectomy. *J Urol* 2010; **184**: 136
70. Eandi JA, Link BA, Nelson RA et al: Robotic assisted laparoscopic salvage prostatectomy for radiation resistant prostate cancer. *J Urol* 2010; **183**: 133
71. Kaffenberger SD, Keegan KA, Bansal NK et al: Salvage robotic assisted laparoscopic radical prostatectomy: A single institution, 5-year experience. *J Urol* 2013; **189**: 507
72. Yuh B, Ruel N, Muldrew S et al: Complications and outcomes of salvage robot-assisted radical prostatectomy: A single-institution experience. *BJU Int* 2014; **113**: 769
73. Bates AS, Samavedi S, Kumar A et al: Salvage robot assisted radical prostatectomy: A propensity matched study of perioperative, oncological and functional outcomes. *Eur J Surg Oncol* 2015; **41**: 1540
74. Fernandez RA, Garcia-Hermoso A, Solera-Martinez M et al: Improvement of continence rate with pelvic floor muscle training post-prostatectomy: A meta-analysis of randomized controlled trials. *Urol Int* 2015; **94**: 125
75. Mariotti G, Sciarra A, Gentilucci A et al: Early recovery of urinary continence after radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment. *J Urol* 2009; **181**: 1788
76. Marchiori D, Bertaccini A, Manferrari F et al: Pelvic floor rehabilitation for continence recovery after radical prostatectomy: Role of a personal training re-educational program. *Anticancer Res* 2010; **30**: 553
77. Van Kampen M, De Weerd W, Van Poppel H et al: Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: A randomised controlled trial. *Lancet* 2000; **355**: 98
78. Overgard M, Angelsen A, Lydersen S and Morkved S: Does physiotherapist-guided pelvic floor muscle training reduce urinary incontinence after radical prostatectomy? A randomised controlled trial. *Eur Urol* 2008; **54**: 438
79. Anderson CA, Omar MI, Campbell SE et al: Conservative management for postprostatectomy urinary incontinence. *Cochrane Database Syst Rev* 2015; **1**: Cd001843

80. Baker H, Wellman S and Lavender V: Functional quality-of-life outcomes reported by men treated for localized prostate cancer: A systematic literature review. *Oncol Nurs Forum* 2016; **43**: 199
81. Donovan JL, Hamdy FC, Lane JA et al: Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. *N Engl J Med* 2016; **375**: 1425
82. Stanford JL, Feng Z, Hamilton AS et al: Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The prostate cancer outcomes study. *JAMA* 2000; **283**: 354
83. Seo HJ, Lee NR, Son SK et al: Comparison of robot-assisted radical prostatectomy and open radical prostatectomy outcomes: A systematic review and meta-analysis. *Yonsei Med J* 2016; **57**: 1165
84. De Carlo F, Celestino F, Verri C et al: Retropubic, laparoscopic, and robot-assisted radical prostatectomy: Surgical, oncological, and functional outcomes: A systematic review. *Urol Int* 2014; **93**: 373
85. Lardas M, Liew M, van den Bergh RC et al: Quality of life outcomes after primary treatment for clinically localised prostate cancer: A systematic review. *Euro Urol* 2017; **72**: 869
86. Choo MS, Choi WS, Cho SY et al: Impact of prostate volume on oncological and functional outcomes after radical prostatectomy: Robot-assisted laparoscopic versus open retropubic. *Korean J Urol* 2013; **54**: 15
87. Lucas MG, Bosch RJ, Burkhard FC et al: [European association of urology guidelines on assessment and nonsurgical management of urinary incontinence]. *Actas Urol Esp* 2013; **37**: 199
88. Habashy D, Losco G, Tse V et al: Mid-term outcomes of a male retro-urethral, transobturator synthetic sling for treatment of post-prostatectomy incontinence: Impact of radiotherapy and storage dysfunction. *Neurourol Urodyn* 2017; **36**: 1147
89. Zuckerman JM, Tisdale B and McCammon K: Advance male sling in irradiated patients with stress urinary incontinence. *Can J Urol* 2011; **18**: 6013
90. Fischer MC, Huckabay C and Nitti VW: The male perineal sling: Assessment and prediction of outcome. *J Urol* 2007; **177**: 1414
91. Castle EP, Andrews PE, Itano N et al: The male sling for post-prostatectomy incontinence: Mean followup of 18 months. *J Urol* 2005; **173**: 1657
92. Herschorn S, Bruschini H, Comiter C et al: Surgical treatment of stress incontinence in men. *Neurourol Urodyn* 2010; **29**: 179
93. Soto Gonzalez M, Da Cuna Carrera I, Lantaron Caeiro EM et al: Correlation between the 1-hour and 24-hour pad test in the assessment of male patients with post-prostatectomy urinary incontinence. *Prog Urol* 2018; **28**: 536
94. Hosier GW, Tennankore KK, Himmelman JG et al: Overactive bladder and storage lower urinary tract symptoms following radical prostatectomy. *Urology* 2016; **94**: 193
95. Thiruchelvam N, Cruz F, Kirby M et al: A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment. *BJU Int* 2015; **116**: 853
96. Kielb SJ and Clemens JQ: Comprehensive urodynamics evaluation of 146 men with incontinence after radical prostatectomy. *Urology* 2005; **66**: 392
97. Chung DE, Dillon B, Kurta J et al: Detrusor underactivity is prevalent after radical prostatectomy: Aurodynamic study including risk factors. *Can Urol Assoc J* 2013; **7**: E33
98. Gomha MA and Boone TB: Voiding patterns in patients with post-prostatectomy incontinence: Urodynamic and demographic analysis. *J Urol* 2003; **169**: 1766
99. Gormley EA, Lightner DJ, Burgio KL et al: Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/sufu guideline. *J Urol* 2012; **188**: 2455
100. Gormley EA, Lightner DJ, Faraday M and Vasavada SP: Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/sufu guideline amendment. *J Urol* 2015; **193**: 1572
101. Ficazzola MA and Nitti VW: The etiology of post-radical prostatectomy incontinence and correlation of symptoms with urodynamic findings. *J Urol* 1998; **160**: 1317
102. Kobashi KC, Albo ME, Dmochowski RR et al: Surgical treatment of female stress urinary incontinence: AUA/sufu guideline. *J Urol* 2017; **198**: 875
103. Biardeau X, Aharony S, Campeau L and Corcos J: Artificial urinary sphincter: Report of the 2015 consensus conference. *Neurourol Urodyn* 2016; **35 Suppl 2**: S8
104. Newman DK, Guzzo T, Lee D and Jayadevappa R: An evidence-based strategy for the conservative management of the male patient with incontinence. *Curr Opin Urol* 2014; **24**: 553
105. Wilson L, Brown JS, Shin GP et al: Annual direct cost of urinary incontinence. *Obstet Gynecol* 2001; **98**: 398
106. Cooperberg MR, Master VA and Carroll PR: Health related quality of life significance of single pad urinary incontinence following radical prostatectomy. *J Urol* 2003; **170**: 512
107. Moore KN, Schieman S, Ackerman T et al: Assessing comfort, safety, and patient satisfaction with three commonly used penile compression devices. *Urology* 2004; **63**: 150

108. Kyle G: The use of urinary sheaths in male incontinence. *Br J Nurs* 2011; **20**: 338
109. Robinson J: Continence: Sizing and fitting a penile sheath. *Br J Community Nurs* 2006; **11**: 420
110. Barry MJ and Edgman-Levitan S: Shared decision making--pinnacle of patient-centered care. *N Engl J Med* 2012; **366**: 780
111. Greenfield S, Kaplan S and Ware JE, Jr.: Expanding patient involvement in care. Effects on patient outcomes. *Ann Intern Med* 1985; **102**: 520
112. Greenfield S, Kaplan SH, Ware JE, Jr. et al: Patients' participation in medical care: Effects on blood sugar control and quality of life in diabetes. *J Gen Intern Med* 1988; **3**: 448
113. Kaplan SH, Greenfield S and Ware JE, Jr.: Assessing the effects of physician-patient interactions on the outcomes of chronic disease. *Med Care* 1989; **27**: S110
114. Guadagnoli E and Ward P: Patient participation in decision-making. *Soc Sci Med* 1998; **47**: 329
115. Rehder P and Gozzi C: Transobturator sling suspension for male urinary incontinence including post-radical prostatectomy. *Eur Urol* 2007; **52**: 860
116. Nager CW, Brubaker L, Litman HJ et al: A randomized trial of urodynamic testing before stress-incontinence surgery. *N Engl J Med* 2012; **366**: 1987
117. Agarwal A, Rathi S, Patnaik P et al: Does preoperative urodynamic testing improve surgical outcomes in patients undergoing the transobturator tape procedure for stress urinary incontinence? A prospective randomized trial. *Korean J Urol* 2014; **55**: 821
118. Perez LM and Webster GD: Successful outcome of artificial urinary sphincters in men with post-prostatectomy urinary incontinence despite adverse implantation features. *J Urol* 1992; **148**: 1166
119. Trigo-Rocha F, Gomes CM and Pompeo ACL: Prospective study evaluating efficacy and safety of adjustable continence therapy (proact) for post radical prostatectomy urinary incontinence. *Urology* 2006; **67**: 965
120. Lai HH, Hsu EI and Boone TB: Urodynamic testing in evaluation of postradical prostatectomy incontinence before artificial urinary sphincter implantation. *Urology* 2009; **73**: 1264
121. Thiel DD, Young PR, Broderick GA et al: Do clinical or urodynamic parameters predict artificial urinary sphincter outcome in post-radical prostatectomy incontinence? *Urology* 2007; **69**: 315
122. Ballert KN and Nitti VW: Association between detrusor overactivity and postoperative outcomes in patients undergoing male bone anchored perineal sling. *J Urol* 2010; **183**: 641
123. Twiss C, Fleischmann N and Nitti VW: Correlation of abdominal leak point pressure with objective incontinence severity in men with post-radical prostatectomy stress incontinence. *Neurourol Urodyn* 2005; **24**: 207
124. Huckabay C, Twiss C, Berger A and Nitti VW: A urodynamics protocol to optimally assess men with post-prostatectomy incontinence. *Neurourol Urodyn* 2005; **24**: 622
125. Hoffman D, Vijay V, Peng M et al: Effect of radiation on male stress urinary incontinence and the role of urodynamic assessment. *Urology* 2018;
126. Kaufman AM, Ritchey ML, Roberts AC et al: Decreased bladder compliance in patients with myelomeningocele treated with radiological observation. *J Urol* 1996; **156**: 2031
127. Ghoniem GM, Bloom DA, McGuire EJ and Stewart KL: Bladder compliance in meningomyelocele children. *J Urol* 1989; **141**: 1404
128. Moore KN, Valiquette L, Chetner MP et al: Return to continence after radical retropubic prostatectomy: A randomized trial of verbal and written instructions versus therapist-directed pelvic floor muscle therapy. *Urology* 2008; **72**: 1280
129. Wille S, Sobottka A, Heidenreich A and Hofmann R: Pelvic floor exercises, electrical stimulation and biofeedback after radical prostatectomy: Results of a prospective randomized trial. *J Urol* 2003; **170**: 490
130. Floratos DL, Sonke GS, Rapidou CA et al: Biofeedback vs verbal feedback as learning tools for pelvic muscle exercises in the early management of urinary incontinence after radical prostatectomy. *BJU Int* 2002; **89**: 714
131. Ribeiro LHS, Prota C, Gomes CM et al: Long-term effect of early postoperative pelvic floor biofeedback on continence in men undergoing radical prostatectomy: A prospective, randomized, controlled trial. *J Urol* 2010; **184**: 1034
132. Goode PS, Burgio KL, Johnson TM, 2nd et al: Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: A randomized controlled trial. *JAMA* 2011; **305**: 151
133. Pannek J and Konig JE: Clinical usefulness of pelvic floor reeducation for men undergoing radical prostatectomy. *Urol Int* 2005; **74**: 38
134. Cornel EB, de Wit R and Witjes JA: Evaluation of early pelvic floor physiotherapy on the duration and degree of urinary incontinence after radical retropubic prostatectomy in a non-teaching hospital. *World J Urol* 2005; **23**: 353

135. Filocamo MT, Li Marzi V, Del Popolo G et al: Effectiveness of early pelvic floor rehabilitation treatment for post-prostatectomy incontinence. *Eur Urol* 2005; **48**: 734
136. Sacomani CAR, Zequi SdC, Costa WHd et al: Long-term results of the implantation of the ams 800 artificial sphincter for post-prostatectomy incontinence: A single-center experience. *Int Braz J Urol* 2017; **43**: 07
137. Walsh IK, Williams SG, Mahendra V et al: Artificial urinary sphincter implantation in the irradiated patient: Safety, efficacy and satisfaction. *BJU Int* 2002; **89**: 364
138. Gomha MA and Boone TB: Artificial urinary sphincter for post-prostatectomy incontinence in men who had prior radiotherapy: A risk and outcome analysis. *J Urol* 2002; **167**: 591
139. Litwiller SE, Kim KB, Fone PD et al: Post-prostatectomy incontinence and the artificial urinary sphincter: A long-term study of patient satisfaction and criteria for success. *J Urol* 1996; **156**: 1975
140. Trigo Rocha F, Gomes CM, Mitre AI et al: A prospective study evaluating the efficacy of the artificial sphincter ams 800 for the treatment of postradical prostatectomy urinary incontinence and the correlation between preoperative urodynamic and surgical outcomes. *Urology* 2008; **71**: 85
141. Guillaumier S, Solomon E, Jenks J et al: Radiotherapy is associated with reduced continence outcomes following implantation of the artificial urinary sphincter in men with post-radical prostatectomy incontinence. *Urology Annals* 2017; **9**: 253
142. Kuznetsov DD, Kim HL, Patel RV et al: Comparison of artificial urinary sphincter and collagen for the treatment of postprostatectomy incontinence. *Urology* 2000; **56**: 600
143. Gousse AE, Madjar S, Lambert MM and Fishman IJ: Artificial urinary sphincter for post-radical prostatectomy urinary incontinence: Long-term subjective results. *J Urol* 2001; **166**: 1755
144. Santos ACSDJ, Rodrigues LdO, Azevedo DC et al: Artificial urinary sphincter for urinary incontinence after radical prostatectomy: A historical cohort from 2004 to 2015. *Int Braz J Urol* 2017; **43**: 150
145. Lai HH, Hsu EI, Teh BS et al: 13 years of experience with artificial urinary sphincter implantation at baylor college of medicine. *J Urol* 2007; **177**: 1021
146. Scott FB, Bradley WE and Timm GW: Treatment of urinary incontinence by an implantable prosthetic urinary sphincter. 1974. *J Urol* 2002; **167**: 1125
147. Kretschmer A, Husch T, Thomsen F et al: Complications and short-term explantation rate following artificial urinary sphincter implantation: Results from a large middle european multi-institutional case series. *Urol Int* 2016; **97**: 205
148. Ahyai SA, Ludwig TA, Dahlem R et al: Outcomes of single- vs double-cuff artificial urinary sphincter insertion in low- and high-risk profile male patients with severe stress urinary incontinence. *BJU Int* 2016; **118**: 625
149. O'Connor RC, Lyon MB, Guralnick ML and Bales GT: Long-term follow-up of single versus double cuff artificial urinary sphincter insertion for the treatment of severe postprostatectomy stress urinary incontinence. *Urology* 2008; **71**: 90
150. Wolf JS, Jr., Bennett CJ, Dmochowski RR et al: Best practice policy statement on urologic surgery antimicrobial prophylaxis. *J Urol* 2008; **179**: 1379
151. Le Portz B, Haillot O, Brouziyne M and Saussine C: Surgimesh m-sling((r)) transobturator and prepubic four-arm urethral sling for post-prostatectomy stress urinary incontinence: Clinical prospective assessment at 24 months. *BJU Int* 2016; **117**: 966
152. Soljanik I, Becker AJ, Stief CG et al: Repeat retourethral transobturator sling in the management of recurrent postprostatectomy stress urinary incontinence after failed first male sling. *Eur Urol* 2010; **58**: 767
153. Carmel M, Hage B, Hanna S et al: Long-term efficacy of the bone-anchored male sling for moderate and severe stress urinary incontinence. *BJU Int* 2010; **106**: 1012
154. Xu YM, Zhang XR, Sa YL et al: Bulbourethral composite suspension for treatment of male-acquired urinary incontinence. *Eur Urol* 2007; **51**: 1709
155. Romano SV, Metrebian SE, Vaz F et al: An adjustable male sling for treating urinary incontinence after prostatectomy: A phase iii multicentre trial. *BJU Int* 2006; **97**: 533
156. Ullrich NFE and Comiter CV: The male sling for stress urinary incontinence: Urodynamic and subjective assessment. *J Urol* 2004; **172**: 204
157. Comiter CV: The male sling for stress urinary incontinence: A prospective study. *J Urol* 2002; **167**: 597
158. John H: Bulbourethral composite suspension:: A new operative technique for post-prostatectomy incontinence. *J Urol* 2004; **171**: 1866
159. Wadie BS: A novel technique of bulbourethral sling for post-prostatectomy incontinence. *Scand J Urol Nephrol* 2007; **41**: 398
160. Rehder P, Haab F, Cornu JN et al: Treatment of postprostatectomy male urinary incontinence with the transobturator retroluminal repositioning sling suspension: 3-year follow-up. *Eur Urol* 2012; **62**: 140

161. Zuckerman JM, Henderson K and McCammon K: Transobturator male sling: Is there a learning curve? *Can J Urol* 2013; **20**: 6768
162. Stern JA, Clemens JQ, Tiplitsky SI et al: Long-term results of the bulbourethral sling procedure. *J Urol* 2005; **173**: 1654
163. Hubner WA, Gallistl H, Rutkowski M and Huber ER: Adjustable bulbourethral male sling: Experience after 101 cases of moderate-to-severe male stress urinary incontinence. *BJU Int* 2011; **107**: 777
164. Madjar S, Jacoby K, Giberti C et al: Bone anchored sling for the treatment of post-prostatectomy incontinence. *J Urol* 2001; **165**: 72
165. Giberti C, Gallo F, Schenone M et al: The bone anchor suburethral synthetic sling for iatrogenic male incontinence: Critical evaluation at a mean 3-year followup. *J Urol* 2009; **181**: 2204
166. Bauer RM, Mayer ME, May F et al: Complications of the advance transobturator male sling in the treatment of male stress urinary incontinence. *Urology* 2010; **75**: 1494
167. Comiter C: Surgery for postprostatectomy incontinence: Which procedure for which patient? *Nat Rev Urol* 2015; **12**: 91
168. Cornu JN, Sebe P, Ciofu C et al: The advance transobturator male sling for postprostatectomy incontinence: Clinical results of a prospective evaluation after a minimum follow-up of 6 months. *Eur Urol* 2009; **56**: 923
169. Bauer RM, Soljanik I, Fullhase C et al: Mid-term results for the retroluminal transobturator sling suspension for stress urinary incontinence after prostatectomy. *BJU Int* 2011; **108**: 94
170. Nash S, Aboseif S, Gilling P et al: Four-year follow-up on 68 patients with a new post-operatively adjustable long-term implant for post-prostatectomy stress incontinence: Proact™. *Neurourol Urodyn* 2019; **38**: 248
171. Angulo JC, Schönburg S, Giammò A et al: Systematic review and meta-analysis comparing adjustable transobturator male system (atoms) and adjustable continence therapy (proact) for male stress incontinence. *PLoS One* 2019; **14**: e0225762
172. Larson T, Jhaveri H and Yeung LL: Adjustable continence therapy (proact) for the treatment of male stress urinary incontinence: A systematic review and meta-analysis. *Neurourol Urodyn* 2019; **38**: 2051
173. Tricard T, Song QX, Munier P et al: Adjustable continence therapy (proact) for the treatment of male stress urinary incontinence post-prostatectomy: A systematic review and meta-analysis (2023 update). *World J Urol* 2023; **41**: 1793
174. Noordhoff TC, Scheepe JR and Blok BFM: Outcome and complications of adjustable continence therapy (proact™) after radical prostatectomy: 10 years' experience in 143 patients. *Neurourol Urodyn* 2018; **37**: 1419
175. Finazzi Agrò E, Gregori A, Bianchi D et al: Efficacy and safety of adjustable balloons (proact™) to treat male stress urinary incontinence after prostate surgery: Medium and long-term follow-up data of a national multicentric retrospective study. *Neurourol Urodyn* 2019; **38**: 1979
176. Ricard H, Léon G, Branchereau J et al: Adjustable continence balloons in postprostatectomy incontinence: Outcomes and complications. *Neurourol Urodyn* 2022; **41**: 1414
177. Nestler S, Thomas C, Neisius A et al: Long-term results of proact primary and repeat implantation for treatment of stress urinary incontinence in men. *World J Urol* 2019; **37**: 1173
178. Hubner WA and Schlarp OM: Adjustable continence therapy (proact): Evolution of the surgical technique and comparison of the original 50 patients with the most recent 50 patients at a single centre. *Eur Urol* 2007; **52**: 680
179. Silva LA, Andriolo RB, Atallah AN and da Silva EM: Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery. *Cochrane Database Syst Rev* 2014: Cd008306
180. Gratzke C, Bachmann A, Descazeaud A et al: Eau guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. *Eur Urol* 2015; **67**: 1099
181. Gundian JC, Barrett DM and Parulkar BG: Mayo clinic experience with the as800 artificial urinary sphincter for urinary incontinence after transurethral resection of prostate or open prostatectomy. *Urology* 1993; **41**: 318
182. Kretschmer A, Buchner A, Leidl B et al: Long-term outcome of the retrourethral transobturator male sling after transurethral resection of the prostate. *Int Neurourol J* 2016; **20**: 335
183. Hogewoning CRC, Meij LAM, Pelger RCM et al: Sling surgery for the treatment of urinary incontinence after transurethral resection of the prostate: New data on the virtue male sling and an evaluation of literature. *Urology* 2017; **100**: 187
184. Bastian PJ, Boorjian SA, Bossi A et al: High-risk prostate cancer: From definition to contemporary management. *Eur Urol* 2012; **61**: 1096
185. Hudak SJ and Morey AF: Impact of 3.5 cm artificial urinary sphincter cuff on primary and revision surgery for male stress urinary incontinence. *J Urol* 2011; **186**: 1962
186. Manunta A, Guille F, Patard JJ and Lobel B: Artificial sphincter insertion after radiotherapy: Is it worthwhile? *BJU Int* 2000; **85**: 490

187. Ravier E, Fassi-Fehri H, Crouzet S et al: Complications after artificial urinary sphincter implantation in patients with or without prior radiotherapy. *BJU Int* 2015; **115**: 300
188. Sathianathen NJ, McGuigan SM and Moon DA: Outcomes of artificial urinary sphincter implantation in the irradiated patient. *BJU Int* 2014; **113**: 636
189. Bates AS, Martin RM and Terry TR: Complications following artificial urinary sphincter placement after radical prostatectomy and radiotherapy: A meta-analysis. *BJU Int* 2015; **116**: 623
190. Hird AE and Radomski SB: Artificial urinary sphincter erosion after radical prostatectomy in patients treated with and without radiation. *Can Urol Assoc J* 2015; **9**: E354
191. Wright HC, McGeagh K, Richter LA et al: Transobturator sling for post-prostatectomy incontinence: Radiation's effect on efficacy/satisfaction. *Can J Urol* 2017; **24**: 8998
192. Dosanjh A, Baldwin S, Mytton J et al: A national study of artificial urinary sphincter and male sling implantation after radical prostatectomy in England. *BJU Int* 2020; **125**: 467
193. Angulo JC, Ruiz S, Lozano M et al: Systematic review and meta-analysis comparing adjustable transobturator male system (atoms) and male readjustment mechanical external (remeex) system for post-prostatectomy incontinence. *World J Urol* 2021; **39**: 1083
194. Altan M, Asi T, Bilen CY and Ergen A: Adjustable perineal male sling for the treatment of urinary incontinence: Long-term results. *Urology* 2017; **106**: 216
195. Friedl A, Mühlstädt S, Zachoval R et al: Long-term outcome of the adjustable transobturator male system (atoms): Results of a European multicentre study. *BJU Int* 2017; **119**: 785
196. Giammò A, Ammirati E, Tullio A et al: Implant of atoms® system for the treatment of postoperative male stress urinary incontinence: Results of a single centre. *Int Braz J Urol* 2019; **45**: 127
197. Redmond EJ, Nadeau G, Tu LM et al: Multicentered assessment of clinical outcomes and factors associated with failure of the adjustable transobturator male system (atoms). *Urology* 2021; **148**: 280
198. Mühlstädt S, Angulo JC, Mohammed N et al: Complications of the urinary incontinence system atoms: Description of risk factors and how to prevent these pitfalls. *World J Urol* 2020; **38**: 1795
199. Li Marzi V, Morselli S, Fusco F et al: Advance xp® male sling can be an effective and safe treatment for post-prostatectomy stress urinary incontinence also in patients with prior history of external beam radiation therapy: A multicentric experience. *Surg Innov* 2021; **28**: 723
200. Poon SA, Silberstein JL, Savage C et al: Surgical practice patterns for male urinary incontinence: Analysis of case logs from certifying American urologists. *J Urol* 2012; **188**: 205
201. Elsergany R, Elgamasy AN and Ghoniem GM: Transurethral collagen injection for female stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct* 1998; **9**: 13
202. Cespedes RD, Leng WW and McGuire EJ: Collagen injection therapy for postprostatectomy incontinence. *Urology* 1999; **54**: 597
203. Kim PH, Pinheiro LC, Atoria CL et al: Trends in the use of incontinence procedures after radical prostatectomy: A population based analysis. *J Urol* 2013; **189**: 602
204. Westney OL, Bevan-Thomas R, Palmer JL et al: Transurethral collagen injections for male intrinsic sphincter deficiency: The University of Texas-Houston experience. *J Urol* 2005; **174**: 994
205. Secin FP, Martinez-Salamanca JI and Eilber KS: [limited efficacy of permanent injectable agents in the treatment of stress urinary incontinence after radical prostatectomy]. *Arch Esp Urol* 2005; **58**: 431
206. Kylmala T, Tainio H, Raitanen M and Tammela TL: Treatment of postoperative male urinary incontinence using transurethral macroplastique injections. *J Endourol* 2003; **17**: 113
207. Imamoglu MA, Tuygun C, Bakirtas H et al: The comparison of artificial urinary sphincter implantation and endourethral macroplastique injection for the treatment of postprostatectomy incontinence. *Eur Urol* 2005; **47**: 209
208. Yokoyama T, Nishiguchi J, Watanabe T et al: Comparative study of effects of extracorporeal magnetic innervation versus electrical stimulation for urinary incontinence after radical prostatectomy. *Urology* 2004; **63**: 264
209. Fode M and Sonksen J: Penile vibratory stimulation in the treatment of post-prostatectomy incontinence: A randomized pilot study. *Neurourol Urodyn* 2015; **34**: 117
210. Guyatt G, Oxman AD, Akl EA et al: Grade guidelines: 1. Introduction-grade evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011; **64**: 383
211. Raj GV, Peterson AC and Webster GD: Outcomes following erosions of the artificial urinary sphincter. *J Urol* 2006; **175**: 2186
212. Kaufman MR, Milam DF, Johnsen NV et al: Prior radiation therapy decreases time to idiopathic erosion of artificial urinary sphincter: A multi-institutional analysis. *J Urol* 2018; **199**: 1037
213. Huang MM, Huffman P, Dani H et al: Association between previous pelvic radiation and all-cause and cause-specific failure of replacement artificial urinary sphincters. *J Urol* 2022; **207**: 1268

214. Brant WO, Erickson BA, Elliott SP et al: Risk factors for erosion of artificial urinary sphincters: A multicenter prospective study. *Urology* 2014; **84**: 934
215. Sayedahmed K, Olianias R, Kaftan B et al: Impact of previous urethroplasty on the outcome after artificial urinary sphincter implantation: A prospective evaluation. *World J Urol* 2020; **38**: 183
216. Mann RA, Kasabwala K, Buckley JC et al: The "fragile" urethra as a predictor of early artificial urinary sphincter erosion. *Urology* 2022; **169**: 233
217. McGeady JB, McAninch JW, Truesdale MD et al: Artificial urinary sphincter placement in compromised urethras and survival: A comparison of virgin, radiated and reoperative cases. *J Urol* 2014; **192**: 1756
218. McKibben MJ, Shakir N, Fuchs JS et al: Erosion rates of 3.5-cm artificial urinary sphincter cuffs are similar to larger cuffs. *BJU Int* 2019; **123**: 335
219. Simhan J, Morey AF, Singla N et al: 3.5 cm artificial urinary sphincter cuff erosion occurs predominantly in irradiated patients. *J Urol* 2015; **193**: 593
220. Queissert F, Huesch T, Kretschmer A et al: Artificial urinary sphincter cuff size predicts outcome in male patients treated for stress incontinence: Results of a large central european multicenter cohort study. *Int Neurourol J* 2019; **23**: 219
221. Wilson S, Delk J, 2nd, Henry GD and Siegel AL: New surgical technique for sphincter urinary control system using upper transverse scrotal incision. *J Urol* 2003; **169**: 261
222. Guralnick ML, Miller E, Toh KL and Webster GD: Transcorporal artificial urinary sphincter cuff placement in cases requiring revision for erosion and urethral atrophy. *J Urol* 2002; **167**: 2075
223. Moser DC, Kaufman MR, Milam DF et al: Impact of radiation and transcorporeal artificial sphincter placement in patients with prior urethral cuff erosion: Results from a retrospective multicenter analysis. *J Urol* 2018; **200**: 1338
224. Linder BJ, de Cogain M and Elliott DS: Long-term device outcomes of artificial urinary sphincter reimplantation following prior explantation for erosion or infection. *J Urol* 2014; **191**: 734
225. Raj GV, Peterson AC, Toh KL and Webster GD: Outcomes following revisions and secondary implantation of the artificial urinary sphincter. *J Urol* 2005; **173**: 1242
226. Kowalczyk JJ, Nelson R and Mulcahy JJ: Successful reinsertion of the artificial urinary sphincter after removal for erosion or infection. *Urology* 1996; **48**: 906
227. Motley RC and Barrett DM: Artificial urinary sphincter cuff erosion. Experience with reimplantation in 38 patients. *Urology* 1990; **35**: 215
228. Lai HH and Boone TB: Complex artificial urinary sphincter revision and reimplantation cases--how do they fare compared to virgin cases? *J Urol* 2012; **187**: 951
229. Viers BR, Linder BJ, Rivera ME et al: Long-term quality of life and functional outcomes among primary and secondary artificial urinary sphincter implantations in men with stress urinary incontinence. *J Urol* 2016; **196**: 838
230. Brucker BM, Demirtas A, Fong E et al: Artificial urinary sphincter revision: The role of ultrasound. *Urology* 2013; **82**: 1424
231. Bauer RM, Mayer ME, Gratzke C et al: Prospective evaluation of the functional sling suspension for male postprostatectomy stress urinary incontinence: Results after 1 year. *Euro Urol* 2009; **56**: 928
232. Ajay D, Zhang HJ, Gupta S et al: The artificial urinary sphincter is superior to a secondary transobturator male sling in cases of a primary sling failure. *J Urol* 2015; **194**: 1038
233. Fisher MB, Aggarwal N, Vuruskan H and Singla AK: Efficacy of artificial urinary sphincter implantation after failed bone-anchored male sling for postprostatectomy incontinence. *Urology* 2007; **70**: 942
234. Lentz AC, Peterson AC and Webster GD: Outcomes following artificial sphincter implantation after prior unsuccessful male sling. *J Urol* 2012; **187**: 2149
235. Singla N, Siegel JA, Simhan J et al: Does pressure regulating balloon location make a difference in functional outcomes of artificial urinary sphincter? *J Urol* 2015; **194**: 202
236. Maximilien B, Aublea A, Gillibert A et al: Urethral pressure controlled balloon refilling or balloon change for artificial sphincter secondary procedure? *Prog Urol* 2018; **28**: 209
237. Mock S, Dmochowski RR, Brown ET et al: The impact of urethral risk factors on transcorporeal artificial urinary sphincter erosion rates and device survival. *J Urol* 2015; **194**: 1692
238. Bryan DE, Mulcahy JJ and Simmons GR: Salvage procedure for infected noneroded artificial urinary sphincters. *J Urol* 2002; **168**: 2464
239. Rozanski AT, Tausch TJ, Ramirez D et al: Immediate urethral repair during explantation prevents stricture formation after artificial urinary sphincter cuff erosion. *J Urol* 2014; **192**: 442
240. Aaronson DS, Elliott SP and McAninch JW: Transcorporal artificial urinary sphincter placement for incontinence in high-risk patients after treatment of prostate cancer. *Urology* 2008; **72**: 825

241. Trost L and Elliott D: Small intestinal submucosa urethral wrap at the time of artificial urinary sphincter placement as a salvage treatment option for patients with persistent/recurrent incontinence following multiple prior sphincter failures and erosions. *Urology* 2012; **79**: 933
242. Margreiter M, Farr A, Sharma V et al: Urethral buttressing in patients undergoing artificial urinary sphincter surgery. *J Urol* 2013; **189**: 1777
243. Chertack N, Chaparala H, Angermeier KW et al: Foley or fix: A comparative analysis of reparative procedures at the time of explantation of artificial urinary sphincter for cuff erosion. *Urology* 2016; **90**: 173
244. Chertack NA, Caldwell KM, Joice GA et al: Long-term lower urinary tract sequelae following aus cuff erosion. *Neurourol Urodyn* 2022; **41**: 229
245. Salonia A, Burnett AL, Graefen M et al: Prevention and management of postprostatectomy sexual dysfunctions part 2: Recovery and preservation of erectile function, sexual desire, and orgasmic function. *Eur Urol* 2012; **62**: 273
246. Mehta A, Deveci S and Mulhall JP: Efficacy of a penile variable tension loop for improving climacturia after radical prostatectomy. *BJU Int* 2013; **111**: 500
247. Jain R, Mitchell S, Laze J and Lepor H: The effect of surgical intervention for stress urinary incontinence (ui) on post-prostatectomy ui during sexual activity. *BJU Int* 2012; **109**: 1208
248. Christine B BA: Climacturia: An under-addressed sequela of radical prostatectomy, but treatment is only a sling away. *J Urol* 2016; **195**: e636
249. Yafi FA, Andrianne R, Brady J et al: "Andrianne mini-jupette" graft at the time of inflatable penile prosthesis placement for the management of post-prostatectomy climacturia and minimal urinary incontinence. *J Sex Med* 2018; **15**: S146
250. Hampson LA, McAninch JW and Breyer BN: Male urethral strictures and their management. *Nat Rev Urol* 2014; **11**: 43
251. Keihani S, Chandrapal JC, Peterson AC et al: Outcomes of urethroplasty to treat urethral strictures arising from artificial urinary sphincter erosions and rates of subsequent device replacement. *Urology* 2017; **107**: 239
252. Kumar R and Nehra A: Dual implantation of penile and sphincter implants in the post-prostatectomy patient. *Curr Urol Rep* 2007; **8**: 477
253. Zafirakis H, Wang R and Westney OL: Combination therapy for male erectile dysfunction and urinary incontinence. *Asian J Androl* 2008; **10**: 149
254. Segal RL, Cabrini MR, Harris ED et al: Combined inflatable penile prosthesis-artificial urinary sphincter implantation: No increased risk of adverse events compared to single or staged device implantation. *J Urol* 2013; **190**: 2183
255. Mancini JG, Kizer WS, Jones LA et al: Patient satisfaction after dual implantation of inflatable penile and artificial urinary sphincter prostheses. *Urology* 2008; **71**: 893
256. Patel N, Golan R, Halpern JA et al: A contemporary analysis of dual inflatable penile prosthesis and artificial urinary sphincter outcomes. *J Urol* 2019; **201**: 141
257. Weissbart SJ, Chughtai B, Elterman D and Sandhu JS: Management of anastomotic stricture after artificial urinary sphincter placement in patients who underwent salvage prostatectomy. *Urology* 2013; **82**: 476